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A Síndrome de Rett (RTT) é uma doença rara do neurodesenvolvimento e de causa 
genética que afeta cerca de 1:10000 raparigas em todo o mundo. Esta doença caracteriza-se 
por um aparente normal desenvolvimento até aos 6 a 18 meses de idade, seguido de uma fase 
de regressão, na qual ocorre a perda das capacidades já adquiridas. Entre outros sintomas, 
destacam-se: severa disfunção cognitiva e motora, epilepsia e aparecimento de movimentos 
estereotipados e repetitivos das mãos com progressiva perda da sua funcionalidade.  
Estudos genéticos mostraram que esta síndrome se deve, maioritariamente, a 
mutações no gene methyl CpG binding protein 2 (MECP2) localizado no cromossoma X. Este gene 
codifica a proteína MeCP2, um modulador epigenético e regulador da estrutura da cromatina, 
com funções primordiais no desenvolvimento e maturação do Sistema Nervoso Central 
(central nervous system - CNS). Uma das proteínas cuja expressão é controlada pela MeCP2 é 
o fator neurotrófico derivado do cérebro (brain-derived neurotrophic factor - BDNF), 
conhecido pelas suas importantes funções na maturação e diferenciação celular, plasticidade 
sináptica e sobrevivência neuronal. Consequentemente, alterações na MeCP2 podem 
comprometer os níveis de expressão e função do BDNF. 
Estudos em modelos animais, que reproduzem a maioria dos sintomas característicos 
da RTT, demonstraram que o aumento da expressão do BDNF consegue reverter parcialmente 
algumas das disfunções e sintomas desta síndrome. Contudo, o uso terapêutico de BDNF não 
é ainda exequível uma vez que a barreira hematoencefálica (blood-brain barrier - BBB) é 
impermeável a este fator neurotrófico, impedindo-o de chegar ao cérebro e desempenhar 
adequadamente as suas funções. Na tentativa de facilitar os efeitos do BDNF, têm-se 
desenvolvido novas estratégias envolvendo, por exemplo, a utilização de fármacos que 
atravessando a BBB potenciem a ação neuroprotetora do BDNF. Um dos fármacos que tem 
merecido particular atenção é a adenosina. A adenosina é um neuromodulador do CNS que 
exerce as suas funções através da ativação de quatro recetores, A1, A2A, A3 e A2B. Em particular, 
a ativação dos recetores A2A é fulcral para a manutenção dos níveis de BDNF e do seu recetor, 
TrkB-FL, assim como para os seus efeitos sinápticos. É de realçar que, o sistema 
adenosinérgico, para além de ser crucial na sinalização mediada pelo BDNF, também tem um 
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papel de destaque no controlo da excitabilidade sináptica através da ativação dos recetores 
inibitórios do tipo A1, reconhecidos como potenciais alvos terapêuticos no controlo da 
epilepsia. Estas ações da adenosina sugerem a possibilidade de este neuromodulador também 
estar afetado na RTT. De facto, estudos preliminares, realizados no nosso laboratório, 
apontam para a existência de uma disfunção do sistema adenosinérgico em associação à 
desregulação já conhecida da sinalização mediada pelo BDNF na RTT.  
Assim, este projeto teve como principal objetivo fazer a caracterização detalhada do 
sistema adenosinérgico e da sinalização mediada pelo BDNF, através da utilização de: 1) 
modelo animal, ratinho mutante Mecp2 knockout (KO); 2) modelo humano, neurónios 
derivados de células pluripotentes induzidas humanas (human induced pluripotent stem cells 
- hIPSCs) de pacientes com RTT e 3) tecido cerebral humano recolhido durante autópsia 
realizada a paciente com RTT.  
Ensaios de ligação anteriormente realizados já tinham mostrado um aumento dos 
níveis proteicos dos recetores A1 em amostras de córtex cerebral de ratinhos Mecp2 KO 
quando comparado com amostras de ratinhos WT, não havendo alterações na expressão do 
seu mRNA. No presente trabalho, ensaios de Western-Blot revelaram uma diminuição 
significativa dos recetores do tipo A2A no córtex cerebral dos ratinhos Mecp2 KO, não tendo 
sido contudo, detetadas alterações nos níveis de expressão do mRNA avaliados por polimerase 
chain reaction (PCR) quantitativo. Curiosamente, registos eletrofisiológicos realizados no 
hipocampo destes animais sugerem uma diminuição dos níveis de adenosina endógena, que 
não é atribuível a variações nos níveis proteicos de um dos enzimas responsáveis pela 
degradação da adenosina, adenosina cinase (Adenosine Kinase - ADK).  
No modelo animal, os resultados, obtidos por ELISA, confirmaram que os níveis 
proteicos de BDNF estão bastante diminuídos. Semelhante resultado foi obtido para os níveis 
dos seus recetores TrkB-FL quando avaliados pela técnica de Western Blot, não havendo, 
contudo, alterações significativas nos recetores truncados deste fator neurotrófico (TrkB-Tc). 
No entanto, os níveis de expressão de mRNA para as duas isoformas do recetor TrkB (TrkB-FL 
e TrkB-T1 – isoforma truncada) não mostraram alterações significativas. 
Em neurónios derivados de hIPSCs, a avaliação dos recetores adenosinérgicos (A1 e 
A2A), do BDNF e dos recetores TrkB, efetuada através de PCR quantitativo, demonstrou uma 
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considerável variabilidade, não sendo por isso possível fazer uma comparação com os 
resultados obtidos no modelo animal. Relativamente ao estudo dos níveis proteicos de BDNF, 
neste modelo, observou-se uma tendência para aumento e, pelo contrário, registou-se uma 
tendência para diminuição dos níveis de expressão dos seus recetores.  
Os resultados obtidos a partir da amostra de córtex temporal de uma paciente com 
RTT mostraram um aumento da expressão de mRNA dos recetores A1 e uma diminuição da 
expressão de mRNA dos recetores A2A. No que respeita aos recetores TrkB, observou-se um 
aumento da expressão do mRNA que codifica para o recetor TrkB-FL. Não se observou 
contudo alteração no mRNA para o recetor TrkB-T1. Em associação, não foi observada 
alteração na expressão de mRNA que codifica para o BDNF. 
Neste trabalho, o maior problema encontrado foi a variabilidade observada, não só 
entre as linhas celulares provenientes de indivíduos do mesmo género, como também entre 
as rondas independentes de diferenciação da mesma linha parental. Parte dessa variabilidade 
pode estar relacionado com as múltiplas alterações genéticas e epigenéticas que ocorrem 
durante os procedimentos de reprogramação e de diferenciação, tais como a fixação de 
mutações aleatórias esporádicas e a inativação aleatória do cromossoma X em linhas 
femininas. Uma outra importante fonte de variabilidade é a eficiência da produção de 
neurónios corticais, que é propensa a flutuar comprometendo os resultados. Ainda que alguns 
resultados mostrem tendências concordantes entre os modelos estudados, é difícil retirar 
conclusões a partir destes, o que é ainda mais agravado pelo reduzido tamanho da amostra.  
Globalmente, os resultados apontam para uma disfunção na sinalização mediada quer 
pelo BDNF quer pelo sistema adenosinérgico, sugerindo um possível envolvimento de ambos 
na fisiopatologia da doença. Estas evidências abrem novas perspetivas para a intervenção 














Rett Syndrome (RTT) is a genetic neurodevelopmental disorder, with an incidence of 
1:10,000 female live births. This disorder is the main genetic cause of intellectual disability in 
females and it is mainly caused by mutations in the methyl-CpG binding protein 2 (MECP2) 
gene.  
The MeCP2 protein, codified by the MECP2 gene, is an epigenetic modulator that 
controls chromatin structure. This protein is known to modulate the expression of brain-
derived neurotrophic factor (BDNF), a neurotrophin with essential functions in cell 
differentiation, synaptic plasticity and survival. Furthermore, BDNF overexpression can 
partially ameliorate some RTT associated symptoms. Thus, therapeutic strategies designed at 
delivering BDNF to the brain could be a breakthrough for RTT. However, this strategy has been 
hampered by the inability of BDNF to cross the blood-brain barrier (BBB). The development of 
new therapeutic strategies is, therefore, of the outmost importance. 
The adenosine is a neuromodulator that acts through the activation of four different 
receptors: A1R, A2AR, A2BR and A3R. The two most well characterized receptors in the brain are 
the A1R and A2AR and their manipulation has been suggested for the treatment of several 
neurological pathologies. Given that, the activation of A2AR is known to potentiate BDNF 
synaptic actions in healthy animals, one could anticipate that the activation of these 
adenosine receptors could be a potential therapeutic strategy.  On the other hand, most of 
RTT patients have epilepsy, a pathology where adenosine system might be affected. However, 
until recently, there was no available information about the contribution of the adenosinergic 
system to the pathophysiology of RTT. To overcome this gap in knowledge, our lab has 
developed a new line of research on this topic. The main goal of this project was to further 
characterize both the adenosinergic system and the BDNF signalling in RTT. This goal was 
achieved by using: i) a well-established animal model, Mecp2 KO mice; ii) human RTT model, 
neurons-derived from RTT patients induced pluripotent stem cells (IPSCs) and iii) post-mortem 
human brain samples from a RTT patient. 
Even though we found some concordant tendencies between the human and the 
mouse models, given the high variability observed in the human material, no clear conclusions 
can be drawn. This is certainly aggravated by the small sample size that, in the future, could 
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be solved by increasing not only the number of patient-derived hIPSCs lines but also by 
increasing the amount of independent rounds of differentiation. The availability of more post-
mortem samples would also be an important asset.  
Overall, the here presented results clearly show a dysfunction in BDNF signalling and 
in the adenosinergic system, suggesting that both systems are involved in the pathophysiology 











1.1 Rett Syndrome 
Rett Syndrome (RTT, OMIM 312750) is a progressive neurodevelopmental disorder that 
affects brain development during early childhood (Chahrour and Zoghbi, 2007; Banerjee et al., 
2012). This rare syndrome, with an incidence of approximately 1 in 10,000 female live births 
(Chahrour and Zoghbi, 2007) was first described in 1966 by Dr. Andreas Rett (Rett, 1966) but 
only 17 years later became recognised by the medical community when Dr. Bengt Hagberg 
and colleagues described 35 RTT cases (Hagberg et al., 1983). Children have an apparently 
normal development until 6-18 months of age when a regression phase starts with loss of 
previously acquired skills (Chahrour and Zoghbi, 2007; Bedogni et al., 2014). Patients develop 
typical symptoms grouped in 4 clinical stages: i) developmental stagnation; ii) rapid 
regression; iii) stationary stage and iv) motor deterioration (Figure 1.1) (Abreu, 2014; 
Chahrour and Zoghbi, 2007).  
The most prominent features in girls with RTT are the development of stereotypic hand 
movements with a decline of purposed hand movements, stagnation of neuromotor 
development, severe cognitive impairment, seizures (epilepsy), autistic features and 
autonomic dysfunctions (reviewed by Chahrour and Zoghbi, 2007). RTT patients can live until 
sixty/seventy years of age in spite of their severely affected physical condition (Chahrour and 
Zoghbi, 2007). 
In 1999 Amir and colleagues described mutations in the MECP2 gene (methyl-CpG binding 
protein 2) as the cause of RTT (Amir et al., 1999). This gene codifies the MeCP2 protein and is 
located in X chromosome, explaining the high prevalence of this disorder in the female gender 







1.1.1 Genetic Basis  
RTT represents the most common genetic cause of severe intellectual disability in 
females (Percy and Lane, 2005).  About 99% of RTT cases are sporadic, hindering the initial 
quest of the associated locus (Chahrour and Zoghbi, 2007). However, studies using rare 
familial cases allowed the identification of the locus Xq28 followed by the identification of 
mutations in MECP2 (Amir et al., 1999). Mutations in MECP2 gene appear in 90% of RTT 
classical cases (Liyanage and Rastegar, 2014), missense and nonsense mutations represent 
70% of all mutations, small C-terminal deletions represent 10% and complex 
rearrangements 6% of the cases (reviewed in Chahrour and Zoghbi, 2007). The majority of 
the mutations arise de novo in the paternal germline and involve a C to T transition at CpG 
dinucleotides (Girard et al., 2001; Trappe et al., 2001; Wan et al., 1999). A relationship 
Figure 1.1 - Onset and clinical manifestations of RTT. RTT patients have normal development during the 
first months of life. After this period, starts a phase of developmental stagnation followed by a rapid 
deterioration with loss of acquired speech, loss of purposeful hand use and midline stereotypies. Autistic 
features also emerge and, in advanced stages of the disease, the clinical condition deteriorates with loss of 
motor skills and profound cognitive impairment. In addition, patients suffer from anxiety, seizures, and 
autonomic abnormalities (Chahrour and Zoghbi, 2007). 
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between RTT phenotype and the type of MECP2 mutation has already been shown, where 
truncating mutations and mutations affecting the nuclear localization signals (NLS) of 
MeCP2 protein are associated with a severe RTT phenotype (Amir and Zoghbi, 2000; 
Smeets et al., 2005). 
Atypical cases of RTT (around 10% of RTT patients), are characterized by mutations in 
other genes, namely CDKL5 and FOXG1 genes and display distinct phenotypes (Neul et al., 
2011; Evans et al., 2005; Philippe et al., 2010).  
 
 MeCP2: gene, protein and its functions 
 
MECP2 gene 
MeCP2 was first identified in 1992 by Bird and colleagues (Lewis et al., 1992) and it is 
the most studied protein of the methyl-CpG binding protein family due to its primordial 
functions and link to this specific disorder (reviewed in Liyanage and Rastegar, 2014 and 
Bedogni et al., 2014). 
The MECP2 gene spans approximately 76 Kb, between the Interleukin-1 receptor 
associated kinase gene  (IRAK1) and the Red Opsin gene (RCP) (Liyanage and Rastegar, 
2014). The structure of MECP2 gene, both in human and mouse, is comprised of 4 exons 
(exon 1-4) and 3 introns (intron 1-3) and two different isoforms are generated by 
alternative splicing: MeCP2_e1 and MeCP2_e2 differing only in N-terminal sequence 
(Figure 1.2) (Cheng and Qiu, 2014; Liyanage and Rastegar, 2014). 
These two isoforms have redundant and also non-redundant functions and their 
expression pattern is distinct. MeCP2_e1 is 10 times more abundant in the postnatal 
human brain than MeCP2_e2 and expression studies in the adult mouse brain showed that 
MeCP2_e2 expression is exclusive to the thalamus and cortex layers  (reviewed in Liyanage 
and Rastegar 2014). Loss of MeCP2_e2 isoform does not cause typical symptoms of RTT, 








 The protein structure of MeCP2 is constituted by 5 domains: N-terminal domain (NTD), 
methyl binding domain (MBD), inter domain (ID), transcription repression domain (TRD) 
and C-terminal Domain (CTD) (Figure 1.3a) (Liyanage and Rastegar, 2014).  
Most of the missense mutations in MeCP2-related disorders affect the MBD, required 
for methylation-dependent chromatin binding (Galvão and Thomas, 2005; Kudo et al., 
2003), explaining the inability of MeCP2 to locate and cluster into heterochromatin and its 
retention in the cytoplasm (Stuss et al., 2013). Mutations in the TRD and CTD domain are 
also present in MeCP2-related disorders (Figure 1.3b) (Liyanage and Rastegar, 2014; 
Bedogni et al., 2014).  
MeCP2 is mainly detected in neurons but it is also present in astrocytes, 
oligodendrocytes and microglia (reviewed in Liyanage and Rastegar, 2014; Zachariah et al., 
2012). Its expression is high during embryonic development and low during neuronal 
maturation and synaptogenesis. MECP2 expression starts to increase over to the first 3 
postnatal weeks, reaching a plateau phase until later adult life, where a new increase of 
MeCP2 expression takes place (Shahbazian et al., 2002).  
Figure 1.2 - Structure of MECP2 gene. a – MECP2 is found in the X chromosome (Xq28), between RCP and 
IRAK1 genes. b – MECP2 is composed of four exons (exons 1-4), three introns (1-3) and three 
polyadenylation sites at the 3’UTR. c – Alternative splicing generates two isoforms: MeCP2_e1, encoded by 
exons 1, 3 and 4 and MeCP2_e2 by exons 2, 3 and 4. Translation start site (arrows); coding region (red bars); 







MeCP2 is a multifunctional protein involved in transcriptional regulation and 
modulation of chromatin structure. The two prominent MeCP2 functional domains, MBD 
and TRD, enable multiple functions through direct DNA binding, interaction with other 
proteins or recruitment of essential factors (see Liyanage and Rastegar, 2014; Banerjee et 
al., 2012; Bedogni et al., 2014). Post-translational modifications have been found to 
regulate protein stability and modulate protein activity (reviewed in Liyanage and 
Rastegar, 2014; Cheng and Qiu, 2014).  
The precise role of MeCP2 in transcriptional repression or activation remains 
controversial. MeCP2 was first identified as a transcription repressor since MeCP2 was 
located at methylated promoters and recruited co-repressors like SIN3A and histone 
deacetylases (HDACs) 1 and 2, promoting a global compaction of chromatin (Nikitina et al., 
2007; Klose and Bird, 2004). On the other hand, MeCP2-mediated transcriptional gene 
activation occurs in association with activator complexes containing cAMP response 
Figure 1.3 - MeCP2 protein structure, mutations and associated impairments in RTT. a – MeCP2_e1 and 
MecP2_e2 protein has 498 and 486 amino acids, respectively. Both isoforms have the some functional 
domains: methyl-CpG-binding domain (MBD), transcriptional regression domain (TRD), C-terminal domain 
(CTD) and N-terminal domain (NTD). AT-hook, in grey, allows binding to AT rich DNA. b – Frequently reported 
mutations in MECP2 and affected domains (adapted from Liyanage and Rastegar, 2014). 
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element-binding protein (CREB) (Chahrour et al., 2008). The regulation of brain-derived 
neurotrophic factor (Bdnf) gene by MeCP2, is an example of the paradoxical role of MeCP2 
upon transcriptional regulation. Binding of MeCP2 to the Bdnf promoter represses its 
expression but in Mecp2-deficient mice, BDNF expression levels are decreased (see section 
1.4.1) (reviewed in Li and Pozzo-Miller, 2014).  
 Furthermore, MeCP2 plays also an important role in the regulation of RNA splicing, 
microRNA regulation, and in the regulation of protein synthesis through AKT/mTOR 
pathway, relevant to neuronal differentiation and  maturation (Figure 1.4) (see Cheng and 
Qiu, 2014; Liyanage and Rastegar, 2014; Bedogni et al., 2014). 
 
Given the wide range of cellular activities of the MeCP2, alterations in its functions 
result in impaired brain development and function (Banerjee et al., 2012; Liyanage and 
Rastegar, 2014). However, the exact mechanisms caused by MeCP2 dysfunction that result 
in RTT related pathophysiological features remain undisclosed. To this end, the use of 
MECP2-deficient models is of the outmost importance. 
Figure 1.4 MeCP2 and its functions. Multiple MeCP2 functions are schematized. Involvement of MeCP2 in 
transcriptional repression and activation is associated with specific factors, such as Sin3A and HDAC in 
repression and CREB1 in activation. MeCP2 has also an active role on protein synthesis via AKT/mTOR 
pathway, in chromatin condensation and in alternative splicing (Bedogni et al., 2014). 
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1.2 Rett Syndrome disease modelling 
Several models are currently available to study RTT. The majority of them have been 
developed in mice where the insertion of specific mutations or deletion of large portions 
of the gene result in MECP2 dysfunction (Liyanage and Rastegar, 2014). The recent 
breakthrough in reprogramming of patient-derived fibroblasts into human induced 
pluripotent stem cells (hIPSCs) together with the ability to promote differentiation into 
specific neuronal populations, allows the generation of human disease relevant cell lines 
as disease models. In this chapter, the advantages and disadvantages of each model are 
discussed. 
  
1.2.1 Mouse models 
Several mouse models have been generated in order to understand the cellular 
mechanisms and behavioural traits underlying RTT. The same models have also been used 
to develop and test possible therapeutic strategies (Katz et al., 2012; Liyanage and 
Rastegar, 2014; Banerjee et al., 2012). A good model is characterized by its ability to 
recapitulate the disease phenotype and its utility in translational studies. Therefore,  it is 
important that a considerable overlap between the mouse and human phenotypical traits 
exist as well as reproducibility and robustness between laboratories, as discussed in (Katz 
et al., 2012).  
The established models include mice carrying global alleles and conditional null alleles. 
In the first group, we can distinguish the null mutations (Guy et al., 2001; Chen et al., 2001), 
that are similar to the large deletions found in 10% of RTT patients; truncations and single-
nucleotide mutations, that are more approximate to the mutations found in the majority 
of RTT patients and point mutations (reviewed in Katz et al., 2012). The second group is 
characterized by mice models where: Mecp2 deletions or mutations are cell type specific 
(Calfa et al., 2011b).  
The majority of RTT mice models used are the null despite of only 10% of RTT patients 
present large deletions.  
Due to X chromosome inactivation (XCI), girls affected with RTT present mosaicism for 
the expression of the mutant allele resulting in different degrees of severity. To avoid this 
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confounding effect experiments are typically done in male mice which do not mimic this 
genetic mosaicism but simplify data interpretation (Stearns et al., 2007; Robinson et al., 
2012). Mecp2-null male mice exhibit consistent early abnormalities in motor behaviour, 
within 6 weeks of age, and more severe than in heterozygous females (Pratte et al., 2011; 
Stearns et al., 2007). Other characteristics in common with the human disease are: 
breathing and cardiac abnormalities (Mccauley et al., 2011; Pratte et al., 2011); cognitive 
impairments; anxiety and alterations in social behaviour (Stearns et al., 2007). These 
animals also have reduced brain volume (Stearns et al., 2007) and prototypical features of 
human RTT neuropathology such as smaller neurons, higher neuronal packing density, 
reduced dendritic arbour and abnormal dendritic spines (reviewed in Katz et al., 2012).  
 
1.2.2 Induced Pluripotent Stem Cells (IPSCs) 
 Due to the constraints of isolating neurons from living subjects, initial studies using 
the human brain were performed on post-mortem tissues that are not always well 
preserved, accessible and often represent an end-stage of the disease. On the other hand, 
animal models,  fail to recapitulate in full, the complexity of the human pathology (Jang et 
al., 2014; Amenduni et al., 2011; Chailangkarn et al., 2012). 
Pluripotent human embryonic stem cells were for the first time successfully generated 
from early stages of the human embryo in 1998 (Thomson et al., 1998).  To develop cellular 
models of human disease it is essential to generate cell lines genetically predisposed to 
disease. In 2006, it was demonstrated that the expression of 4 transcription factors (OCT4, 
SOX2, KLF4 and c-MYC) was sufficient to reprogram mice somatic cells, like fibroblasts, to 
a pluripotent state – Induced Pluripotency (Takahashi and Yamanaka, 2006). A similar 
protocol was also  successfully applied to generate hIPSCs (Takahashi et al., 2007). Most 
IPSCs lines are derived by retroviral transduction of dermal fibroblasts due to its availability 
and high reprogramming efficiency (Saporta et al., 2011; Jang et al., 2014; Dajani et al., 
2013; Cheung et al., 2012). IPSCs are pluripotent and can differentiate into any cell type by 
manipulation of the culture environment with growth factors, small molecules and 
extracellular matrix proteins guiding their differentiation into the cell-type of interest 
(Dajani et al., 2013; Saporta et al., 2011)  
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 Recently, neurons-derived from IPSCs emerged as a promising alternative providing a 
new paradigm for the generation and study of human disease-specific neurons  with a 
predominant role in certain neurological/neurodevelopment/neuropsychiatric  
pathologies (Saporta et al., 2011). Once its validity as a model has been demonstrated, it 
could even be used in translational studies and in the screening of potential therapeutic 
strategies (Figure 1.5) (Saporta et al., 2011; Freitas et al., 2012; Jang et al., 2014; 
Chailangkarn et al., 2012).  
 
In the specific case of RTT, this in vitro human neurodevelopmental model, offers an 
excellent opportunity to recapitulate the early stages of development and mimic specific 
biochemical and cellular features of the disease difficult to reproduce in other models 
(Freitas et al., 2012). 
The first RTT-IPSCs were generated in 2009 (Hotta et al., 2009) and multiple studies 
have followed in order to study RTT neuronal and glial phenotype from a 
neurodevelopmental point of view. In these studies, neurons-derived from RTT-hIPSCs 
recapitulate some of the phenotypes already described in the mouse models and observed 
in patients  (reviewed in Dajani et al., 2013). These include, reduced soma/nuclear size, 
lower expression of neuronal markers, reduced dendrite spine density, reduced 
glutamatergic synapse number, altered neuronal morphology, reduction in the transient 
rise of intracellular calcium and decrease in the frequency/amplitude of spontaneous 
excitatory and inhibitory postsynaptic currents (Figure 1.6) (Marchetto et al., 2010). The 
high overlap between the characteristics observed in these studies and the human disease 
Figure 1.5 - Schematic representation of hIPSCs production and possible applications. To generate IPSCs, 
reprogramming of somatic patient-derived cells is achieved using retroviral transduction of four 
pluripotency factors (OCT4, SOX2, c-MYC and KLF4). IPSCs can be differentiated into the desired cell  type 
that allows human disease modelling, to investigate patient-specific cell  therapy and drug screening 
(Yamanaka and Blau, 2010). 
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provides strong support to the utility of neurons-derived from IPSCs as a model to study 
RTT. 
 
Nevertheless, it is important to take into account that this model still requires 
improvement given the newness of this technique. One of the challenges of using hIPSCs 
is to produce differentiated and functional specific cell types. However, the protocols used 
generally result in a heterogeneous cell population, neurons and glia. This could be an 
advantage given the improved neuronal survival when cultured in mixed populations but 
it can create difficulties in data analysis. Therefore, biochemical and gene expression 
analysis cannot be performed without a careful normalization for cell type and their 
proportions (Saporta et al., 2011). Secondly, epigenetic memory of the original cell 
(fibroblast) might not be fully erased, affecting the differentiation potential. Variability 
between cell lines and clones from the same individual in proliferation and differentiation 
potential have been observed, which affect data interpretation (Chailangkarn et al., 2012). 
Figure 1.6 Phenotypical characteristics of neurons-derived from RTT-hIPSCs. As observed in other RTT 
models, neurons derived from RTT-hIPSCs exhibit (a) smaller soma size; (b) reduced dendritic branching; 
(c) less glutamatergic synapses; (d) fewer dendritic spines and (e) decreased frequency of spontaneous 
postsynaptic currents (Chailangkarn et al., 2012). 
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Nevertheless, this can be partially solved by using different clones from the same individual 
or improving of differentiation protocols (Dajani et al., 2013). 
Another specific challenge in X-linked diseases is the random X chromosome 
inactivation process that is not epigenetically stable demanding screening of cellular lines 
to evaluate the proportion of cells expressing the mutant allele (Cheung et al., 2012; Kim 
et al., 2011). Nevertheless, this outcome can also be considered as an advantage since 
isogenic clones expressing either the wild type allele (WT) or the mutant  allele can be 
studied (Ananiev et al., 2011). Finally, generation of individual IPSCs is an expensive and 
time-consuming process which can be exceeded with collaborations between laboratories 
and institutes (Figure 1.7) (Chailangkarn et al., 2012).  
 The continuous improvement of this model could have enormous impact in health by 
contributing to personalized medicine, making predictions about the efficiency of certain 
drugs in individuals, to regenerative medicine and cell-replacement therapies overcoming 





Figure 1.7 - Challenges in RTT-IPSCs modelling. During reprogramming, de novo genetic and epigenetic 
variation appears as a possible problem as well as parental epigenetic memory. In female IPSCs X-
chromosome instability has also to be considered and followed throughout the process. During 
differentiation, clonal variation and optimal differentiation protocol should be taken into account when 






Adenosine is an endogenous purine nucleoside, constituted by an adenine attached to 
a ribose (Figure 1.8) and is ubiquitously distributed throughout the body (Sachdeva and 
Gupta, 2013; Chen et al., 2007). This purine has an essential and vital role in several 
physiologic functions, acting in the synthesis of nucleic acids and ATP, blood supply, 
glucose homeostasis and can produce pharmacological effects in peripheral and central 
nervous system (PNS) (reviewed in Sachdeva and Gupta, 2013). Adenosine has the 
particularity of acting both as a neuromodulator and as a homeostatic modulator in a wide 
variety of systems. As a neuromodulator, adenosine, controls the information flow 
through neuronal circuits and as a homeostatic modulator sends paracrine signals that can 
tone metabolic activity in specific cells of a tissue, allowing a trans-cellular coordinated 
response to changes in the tissue workload (reviewed in Gomes et al., 2011).  
Extracellular adenosine acts through multiple G-protein coupled receptors and it is 
constitutively present in extracellular space at low concentrations (nanomolar range) that 
markedly rise in stressful conditions, like ischemia, hypoxia, excitotoxicity and 
inflammation, having a cytoprotective role (Boison, 2013; Jacobson and Gao, 2012; Chen 
et al., 2007). 
 




1.3.1 Adenosine metabolism 
Adenosine can be formed intra and extracellularly by the action of the enzyme 5’-
nucleotidase on adenosine monophosphate (AMP) (Phillips and Newsholme, 1979) or 
intracellularly by the hydrolysis of S-adenosylhomocysteine (SAH) (Nagata et al., 1984) 
catalysed by SAH hydrolase.  
The intracellular levels of adenosine are controlled by adenosine kinase (ADK), which 
phosphorylates adenosine to produce AMP, and by adenosine deaminase (ADA) resulting 
in the formation of inosine. Small changes in ADK activity rapidly cause dramatic changes 
in intracellular adenosine concentration (Bontemps et al., 1983; Bontemps et al., 1993). 
Several studies have shown that ADK is the primordial enzyme for adenosine clearance 
under baseline conditions, once it has a low-capacity and a low-Km. ADA with an high-
capacity and high-Km acts in adenosine clearance when adenosine levels are excessive 
(Boison et al., 2010).  
Adenosine does not accumulate in synaptic vesicles like the classical 
neurotransmitters, but it is instead released from the cytoplasm into the extracellular 
space through a nucleoside transporter (see e.g. Ribeiro et al., 2002). 
In summary, adenosine homeostasis is determined by three major pathways working 
in a concerted manner: 1) adenosine formation, 2) adenosine removal and 3) adenosine 
uptake by transmembrane transporters (reviewed in Boison, 2013 and Boison et al., 2010). 
The activity of the transporters depends on the intracellular metabolic clearance rate to 
maintain adenosine uptake. This means that under steady-state conditions of adenosine 
production, extracellular adenosine concentration is controlled by intracellular adenosine 
clearance rate (Greene, 2011).  In parallel, since ADK is the main enzyme involved in 
adenosine clearance and the enzymatic reaction is ATP dependent, adenosine 
homeostasis is largely influenced by the energetic status of the cell (Boison, 2013). During 
metabolic stress, the huge increase in adenosine concentration is achieved by the release 
and degradation of adenine nucleotides, such as adenosine triphosphate (ATP), adenosine 
diphosphate (ADP) and AMP by a cascade of ecto-5’nucleotidases, namely CD39 and CD73 




Interestingly, enzymes involved in adenosine degradation have been considered 
promising pharmacological targets for disorders where adenosine levels are deregulated, 
such as epilepsy (Boison, 2012; Boison, 2013). In addition, alterations in the mechanisms 
that control adenosine levels have also been reported, in particular the overexpression of 
ADK has been detected in epileptogenic brain areas (Gouder et al., 2004), highlighting the 
use of this particular enzyme as a possible pharmacological target. 
 
1.3.2 Adenosine receptors 
To the present date, four different receptors have been cloned A1, A2A, A2B and A3 (R). 
A1R and A3R are mainly coupled to Gi proteins, while the A2AR and A2BR act mainly through 
activation of Gs proteins (Ralevic and Burnstock, 1998) though coupling to Gq can also 
occur.  
Figure 1.9 - Adenosine formation and catabolism. Schematic representation of the multiple processes 
involved in the formation, transport and removal of adenosine. Adenosine can be synthetized intracellularly 
by AMP dephosphorylation via nucleotidases or by cleavage of S-adenosylhomocysteine via SAH-hydrolase. 
Extracellularly, adenosine is formed by ectonucleotidades that dephosphorylate AMP, ADP and ATP. 
Adenosine clearance is performed by the adenosine deaminase, intra- and extracellularly and by adenosine 
kinase, only intracellularly. All these processes produce inosine.  Adenosine transport between cytosol and 
extracellular space occurs via membrane nucleotide transporters. ADP - adenosine diphosphate; AMP  -  
adenosine monophosphate; ATP - Adenosine triphosphate; SAH - S- adenosylhomocysteine (adapted from 
Sachdeva and Gupta, 2013). 
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Adenosine receptors (AR) have an extracellular domain comprised of the N-terminal 
and 3 extracellular loops and by an intracellular domain that comprises the C-terminal and 
3 intracellular loops (Figure 1.10) (Sachdeva and Gupta, 2013). In humans, the similarity 
between receptors is greater between A1R and A3R and between A2AR and A2BR (Jacobson 
and Gao, 2012).  
 A1R and A2AR are considered to be the high affinity receptors for adenosine, and in 
basal conditions are probably tonically activated (Dunwiddie and Masino, 2001). Given the 
higher density of A1R and A2AR in the brain comparing to the other adenosine receptors, 









Adenosine A1 receptors 
A1R are the most abundant adenosine receptors in the central nervous system (CNS), 
with higher expression density in the neocortex, cerebellum, hippocampus and dorsal 
horn of spinal cord. They are pre-, post- and nonsynaptically located (Fredholm et al., 
2005). When located postsynaptically they can influence excitatory response controlling 
both N-type Ca2+ channels and NMDA receptors (Mendonça et al., 1995). If located 
nonsynaptically they control the K+ current resulting in neuronal hyperpolarization 
(Greene and Haas, 1991). Besides being expressed in neurons they can also be found in 
astrocytes and microglia (reviewed by Gomes et al., 2011). Moreover, these receptors can 
Figure 1.10 - Adenosine receptor structure. Adenosine receptors are constituted by an N-terminal 
extracellular domain, 3 extracellular loops (E-I, E-II and E-III), a C-terminal intracellular domain and 3 
intracellular loops (C-I, C-II and C-III)  (Sachdeva and Gupta, 2013). 
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also be found in adipose tissue, heart muscle and inflammatory cells like neutrophils 
(reviewed in Sachdeva and Gupta, 2013).  
The activation of A1R promotes the inhibition of adenylyl cyclase due to the activation 
of toxin-sensitive Gi proteins. It can also promote the inhibition of G-protein coupled-
activation of voltage dependent Ca2+ channels and induce PLC activation (Figure 1.11) 
(Rogel et al., 2005). 
A1R activation selectively depresses excitatory transmission and also can decrease 
miniature events in excitatory synapses (Scanziani et al., 1992). 
 
Adenosine A2A receptors 
A2AR are mostly coupled to Gs, which consequently increase intracellular cAMP. In the 
striatum they are also coupled to Golf (Corvol et al., 2001) and, in the hippocampus, there 
is evidence that these receptors can be coupled to Gi/Go (Figure 1.11) (Cunha et al., 1999). 
Besides being postsynaptically highly expressed in the striatopallidal GABAergic neurons 
and in the olfactory bulb (see e.g. Fredholm et al., 2001), the A2AR are also expressed in 
the hippocampus and cortex (see e.g. Ribeiro et al., 2002). These adenosine receptors are 
mostly found in synapses (pre- and postsynaptically) and also in glial cells (reviewed in 
Gomes et al., 2011).  
The A2AR do not have a marked effect on basal synaptic transmission but they play an 
important role in synaptic plasticity (reviewed in Gomes et al., 2011), specially in aged 
animals (Costenla et al., 1999). The ability of A2AR to enhance the activity-dependent 
efficiency of excitatory synapses has been argued to result from: 1) an enhanced release 
of neurotransmitters (Lopes et al., 2002; Rebola et al., 2003) 2) a localized desensitization 
of A1R-mediated inhibition (Lopes et al., 1999); 3) a facilitation of brain-derived 
neurotrophic factor-induced signalling (Fontinha et al., 2008; Diógenes et al., 2011); and 
4) from an enhanced responsiveness of N-methyl-d-aspartate (NMDA) receptors (Rebola 








Adenosine A2B and A3 receptors 
A2BR, like A2AR, are positively coupled to adenylyl cyclase and PLC, through Gq proteins 
(Linden et al., 1999), and are mostly expressed in gastrointestinal tract, bladder, lung and 
mast cells (reviewed in Sachdeva and Gupta 2013). Even though the closest structure 
between A2AR and A2BR and their capacity to activate adenylyl cyclase (Figure 1.11), these 
two receptors have very different functions, being postulated that A2BR could act by a 
different transduction system than adenylyl cyclase. The affinity of these receptors is also 
low, being activated predominantly when adenosine levels are increased (in µM order) 
(Sachdeva and Gupta, 2013).  
A3R can be found in liver, lung, mast cells, eosinophils, neutrophils, testis, heart and 
brain cortex. Similarly to the A1R, A3R activation inhibits adenylyl cyclase and activates 
phospholipase C and D (Figure 1.11) (Abbracchio et al., 1995). They also can promote Ca2+ 
influx and its release from intracellular stores (Jacobson, 1998). Furthermore, given  the 
link between A3R  and the MAPK pathway, the A3R play an important role in cancer, cell 










Figure 1.11 Adenosine signalling pathway. Schematic representation of the pathways activated by 
adenosine. Activation of A1R and A3R inhibits adenylyl cyclase activity through activation of toxin-sensitive 
Gi proteins, increasing PLC activity via Gβγ subunits. A2AR and A2BR activation leads to adenylyl cyclase 
increased activity by Gs protein activation. A2AR activation induces inositol phosphate formation in some 
situations, probably via Gα15 and Gα16 proteins. A2BR activation induces PLC through Gq. All four adenosine 
receptors can couple to MAPK. Ado - adenosine; ADP - adenosine diphosphate; AKT - protein kinase B; AMP 
- adenosine monophosphate; ATP - adenosine triphosphate; CREB - cAMP response element binding 
protein; DAG - diacylglycerol; Ino - inosine; IP3 - inositol 1,4,5-trisphosphate; MAPK - mitogen-activated 
protein kinases; PI3K - phosphatidylinositol 3-kinase; PIP2 - phosphatidylinositol-4,5-bisphosphate; PK - 




1.3.3 Adenosine and pathology 
Dysfunction in the adenosinergic signalling has been associated with several 
pathologies. Therefore, adenosine and its receptors have been pointed out as promising 
pharmacological targets in several disorders: cardiovascular, renal, pulmonary, 
inflammatory, endocrine and neurologic (Figure 1.12) (reviewed in Jacobson and Gao, 
2012).   
Within the neurologic disorders, epilepsy, Huntington’s, Parkinson´s and Alzheimer´s 
diseases are the ones receiving more attention.  
In epilepsy, the role of adenosine as an anti-epileptic drug has been extensively 
studied. Initial evidence came from studies showing that the inhibitory A1R are enriched 
in excitatory synapses, where they were responsible for the inhibition of glutamate 
release, decreasing therefore glutamatergic responsiveness and hyperpolarising neurons. 
These events are highly desirable to counteract epilepsy, characterized by an exacerbated 
and repetitive excitation (see for review Gomes et al., 2011). In addition, levels of 
extracellular adenosine rise during seizures, which could be a hint that adenosine plays an 
important role as an endogenous anti-epileptic molecule (During and Spencer, 1992; 
Berman et al., 2000). Subsequently, several studies have shown that the administration of 
compounds that increase the extracellular levels of adenosine, such as inhibitors of 
adenosine transporters or ADK inhibitors (briefly explored above in chapter 1.3.1), and 
agonists of A1R, attenuate seizures and convulsive activity in animal models (reviewed in  
Boison et al., 2013). However, it was also shown that synaptic A1R have decreased density 
and efficiency in animal models of epilepsy (Glass et al., 1996; Ekonomou et al., 2000) 
which could complicate the manipulation of A1R receptors to modulate inhibition of this 
pathology. Nowadays, the inhibition of the excitatory A2AR is appearing as a new strategy 
to control chronic epilepsy and its blockage, by the use of antagonists, could be an 
alternative (El Yacoubi et al., 2008). 
In Huntington’s disease (HD) the available data points to a possible involvement of A2AR 
on the pathophysiology of this disorder given that several alterations were detected in the 
A2AR gene as well as in the expression levels of the A2AR protein (Varani et al., 2001; Tarditi 
et al., 2006). Moreover, it is known that A2AR have an important role in motor control, in 
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glutamatergic transmission, in neuroinflammation, on metabolism and mitochondrial 
function, all of them altered in HD (reviewed in Gomes et al., 2011). Thus A2AR antagonists 
have been explored as a potential therapeutic strategy since they improve motor function 
and also act as a neuroprotective agent decreasing glutamate levels and consequently 
controlling glutamatergic synapses. However, this topic brings some controversy since 
some studies refer A2AR agonists as a preferential therapeutic target in HD, because A2AR 
activation by its agonists could also facilitate BDNF functions, that are impaired in HD, 
through TrkB transactivation (Sebastião and Ribeiro, 2009) (explored in chapter 1.4.3) and 
at the same time, A2AR antagonism, initially suggested, potentiate NMDA-mediated 
toxicity. (Popoli et al., 2002). 
The role of adenosine in the pathology of Parkinson’s disease (PD) has also been 
described. Since A2AR are involved in motor control (reviewed in Chen et al., 2007), in 
glutamatergic transmission control, neuroinflammation, metabolism and mitochondrial 
function, known to be impaired in PD, modulation of A2AR improves PD. The use of A2AR 
antagonists in PD is more accepted than in HD, and it is now being evaluated in clinical 
trials with the propose to ameliorate motor impairments and promote neuroprotection 
(LeWitt et al., 2008; Hauser et al., 2003). 
The capacity of adenosine to control and integrate cognition and memory, through A1R 
and A2AR, provides the link between adenosine impairment and Alzheimer’s Disease (AD), 
a disorder characterized by the progressive impairment in these two functional capacities 
(Cunha and Agostinho, 2010). It was shown that A1R and A2AR change their density and 
localization pattern in AD brain and that the chronic stress found in these patients also 
upregulates A2AR suggesting that its manipulation could promote neuroprotection 
(reviewed in Gomes et al., 2011). The capacity of A2AR to modulate learning and memory, 
are vastly studied in AD, where an epidemiologic relationship between caffeine 
consumption and AD risk has been shown (Maia and Mendonça, 2002). This relationship 
suggests that the A2AR antagonism achieve by caffeine (A2AR antagonist) consumption 
could decrease AD risk.      
 Even though the A2AR antagonism is beneficial in the above described 
neurodegenerative disorders, the A2AR agonism has emerged as a replacement strategy 
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once it can potentiate BDNF functions, through TrkB facilitation (Numakawa, 2014). This 
is an important breakthrough since BDNF is impaired in these disorders but cannot be 
administrated due to pharmacokinetic issues. 
Despite above mentioned pathologies share some phenotypical traits with RTT, the 




Figure 1.12 - Adenosine receptors are targeted in several disorders. Use of adenosine receptors 
antagonists, agonists or both is widely explored and already applied in the treatment of some disorders 





BDNF was discovered in 1982 (Barde et al., 1982) and it is a member of the neurotrophin 
family that in mammals includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and 
neurotrophin-4/5 (NT-4/5) (Cohen-cory et al., 2011). Axon targeting, neuron growth, 
synapses maturation and synaptic plasticity are some of essential functions executed by 
these signalling molecules, in particular by BDNF (Binder and Scharfman, 2004).  
 
1.4.1 BDNF expression  
The Bdnf gene is composed by four untranslated 5’ exons associated to different 
promotors and one 3’ exon  (Li and Pozzo-Miller, 2014; Binder and Scharfman, 2004). Eight 
different transcripts can be transcribed from this locus but all of them are translated into 
an identical BDNF protein (Li and Pozzo-Miller, 2014). BDNF is synthetized in the 
endoplasmic reticulum (ER) as a precursor protein, pro-BDNF, and proper protein folding 
takes place in the Golgi apparatus. Pro-BDNF is then cleaved both intra- and extracellularly, 
near synapses to produce the mature and active BDNF form (14 kDa) (Binder and 
Scharfman, 2004; Lee et al., 2001). However, some studies have demonstrated that pro-
BDNF is also present in the extracellular space, with a negative regulator function 
promoting apoptosis, inhibiting dendritic complexity and promoting long-term depression 
(LTD) by the activation of the p75 receptor (Barker, 2004). In the rodent brain, BDNF levels 
are low during prenatal development and rise drastically in the postnatal period (Kolbeck 
et al., 1999). Interestingly, this expression pattern coincides with MeCP2 expression 
pattern. Remarkably, it was also observed that BDNF expression remains unaffected 
during presymptomatic stage in Mecp2 knockout (KO) mice (Chang et al., 2006). In 
addition, Bdnf-deficient mice have a phenotype similar to that found in Mecp2 KO models 
(Chang et al., 2006).  Besides, the positive correlation between BDNF and MeCP2 
expression, it has also been shown that MeCP2 binds to Bdnf at methylated CpG sites 
adjacent to A/T runs (Klose et al., 2005), which could occur in association with repressor 
factors, such as HDACs, indicating a negative relation between these two molecules 
(Martinowich et al., 2003). How MeCP2 can modulate BDNF expression has not been fully 
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addressed and therefore the “Dual operation model”, that proposing a dual action of 
MeCP2 upon BDNF expression is widely accepted (see Li and Pozzo-Miller, 2014). 
 
1.4.2 BDNF signalling upon TrkB receptors 
Neurotrophins can bind to one or more tropomyosin-related kinase (Trk) receptors 
members (Binder and Scharfman, 2004). Their action is mediated by the high-affinity full-
length receptors (Trk-FL), which signal through their intrinsic tyrosine kinase activity. 
Neurotrophin binding induces receptor dimerization, which results in kinase activation and 
receptor autophosphorylation on multiples tyrosine residues. This creates binding sites for 
intracellular target proteins via the SH2 domain (Huang and Reichardt, 2003). Truncated 
isoforms of Trk receptors (Trk-Tc), formed by alternative splicing, can also bind 
neurotrophins, but cannot activate classical pathways of full-length receptors. This 
happens because truncated isoforms do not have the intracellular kinase domain (Allen et 
al., 1994). They are also thought to act as negative effectors of full-length Trk receptors 
(Luikart et al., 2003) and may have their own signalling properties (see e.g. Rose et al., 
2003).  
Mature BDNF has high-affinity to TrkB receptors, activating signal transduction 
through these. There are at least three signalling transduction pathways that BDNF can 
trigger: 1) PLC γ pathway, associated to synaptic plasticity BDNF-mediated, which leads to 
protein kinase C activation; 2) PI3K pathway, related to cell survival BDNF functions, which 
activates serine/threonine kinase AKT and 3) MAPK pathway, linked to growth and 
differentiation BDNF functions,  that activates several downstream effectors as shown in 
(Figure 1.13) (Huang and Reichardt, 2003). 
Three different truncated isoforms of TrkB receptor (TrkB-Tc) can be consider: TrkB-
T1, the most abundant truncated isoform in the brain, TrkB-T2 and TrkB-Sch (Luberg et al., 
2010). All of them can inhibit the BDNF activity by acting as dominant negative inhibitors 
of TrkB-FL receptors (Eide, 1996). 





1.4.3 Interaction between adenosine and BDNF 
A close relationship between adenosine receptors and neurotrophic factors, namely 
BDNF, has been found.  
Presynaptic depolarization, that leads to an increase in adenosine extracellular levels 
and consequently to an enhancement of cAMP by A2AR activation trigger hippocampal 
synaptic actions of BDNF (Diógenes et al., 2004). At the same time, A2AR activation can 
transactivate TrkB receptors in the absence of the neurotrophin (Rajagopal et al., 2004; 
Lee and Chao, 2001). It was also seen that A2AR activation can mediate neuroprotection, 
by increasing cell survival  through Trk-dependent and PI3K/AKT pathway, in hippocampal 
neurons after BDNF and NGF withdrawal (Lee and Chao, 2001). Interestingly, it is also 
known that  A2AR are required for normal BDNF expression levels in the  hippocampus 
(Tebano et al., 2008).  
BDNF 
TrkB-FL 
Figure 1.13 BDNF signalling through TrkB full-length (TrkB-FL) receptors. BDNF binding to TrkB-FL receptor 
promotes receptor autophosphorylation and dimerization, activating downstream signalling pathways: 
PI3K (promotes cell survival); MAPK pathway (promotes cell growth and differentiation); and PLCγ 
(activates IP3, which is related with synaptic plasticity). These pathways activate CREB, a transcription factor 
that up-regulates gene expression. Akt - protein kinase B CREB - cAMP response element binding protein; 
DAG - diacylglycerol; Erk - extracellular signal-regulated kinases IP3 - inositol 1,4,5-trisphosphate; MAPK - 
mitogen-activated protein kinases; PI3K - phosphatidylinositol 3-kinase; PLC - phospholipase C (adapted 




During high neuronal activity, such as long-term potentiation (LTP), higher release of 
adenosine or its precursor, ATP, is observed creating the ideal conditions for the interplay 
between A2AR and TrkB-FL receptors (Sebastião and Ribeiro, 2009). Indeed, when A2AR 
activity is blocked or extracellular adenosine is depleted, the facilitatory action of BDNF 
upon LTP is completely lost (Fontinha et al., 2009; Fontinha et al., 2008; Jerónimo-Santos 
et al., 2014).  
Decreased BDNF levels might be involved in neurodegenerative disorders (Connor and 
Dragunow, 1998), diabetic neuropathies (Nitta et al., 2002) and RTT (reviwed in Li and 
Pozzo-Miller, 2014) making the use of BDNF very promising for their treatment. However, 
until now the pharmacological administration of BDNF has not been easy mainly due to 
pharmacokinetic problems. Therefore, the discovery that the activation of A2AR 
potentiates BDNF actions opened a new avenue for potential therapeutic strategies for 












RTT is genetic disorder with severe intellectual disabilities among other symptoms. It is 
known that in RTT brain-derived neurotrophic factor (BDNF) signalling is impaired. Therefore, 
restoring BDNF signalling could be a great breakthrough in the treatment of RTT, but it has 
been hampered by the difficulty of BDNF to reach its target tissue. Given that, the activation 
of A2AR is known to potentiate BDNF synaptic actions in healthy animals, one could anticipate 
that the activation of these adenosine receptors could be a potential therapeutic strategy.  On 
the other hand, most of RTT patients have epilepsy, a pathology where adenosine system 
might be affected and has been largely explored as a potential therapeutic target. However, 
until recently, there was no available information about the contribution of the adenosinergic 
system to the pathophysiology of RTT. To overcome this gap in knowledge, our lab has 
developed a line of research on this topic.    
The present thesis was developed within a broader project that aims at: 
i) the characterization of the adenosinergic system and BDNF signalling in RTT; 
ii) investigating whether drugs that mediate the activation of adenosine receptors, could 
be a breakthrough in RTT treatment by controlling epilepsy through the activation of A1R, and 
potentiating BDNF effects by the activation of A2AR. 
In particular, the main goal of this project was to further characterize both the 
adenosinergic system and the BDNF signalling in RTT. This goal was achieved by using:  
1) a well-established animal model, Mecp2 KO mice; 
2) human RTT model, neurons-derived from RTT patients IPSCs; 










3. Materials and Methods 
 
3.1 Biological Samples 
 
3.1.1 Animals  
The experiments were performed in adult mice, 6 to 10 weeks old,  Mecp2tm1.1Bird/J 
(Mecp2 knockout (KO), deletion of exons 3 and 4 of the Mecp2 gene) (Guy et al., 2001), 
and in wild type (WT) littermates that were used as control. The genotype of animals was 
determined by polymerase chain reaction, as previously described (Guy et al., 2007). 
The animals were housed on a 12 hours light/dark cycle, with food and water provided 
ad libitum. Experiments involving animals were taken into careful consideration in order 
to reduce the number of animals sacrificed. All animals were handled according to the 
Portuguese law on Animal Care and European Union guidelines (86/609/EEC). 
 
3.1.2 Post-mortem Brain Sample 
The brain tissue of an 11 year-old girl affected with RTT (MeCP2 mutation - R255X) who 
died after a severe pneumonia was dissected and different anatomic regions were 
immediately frozen at -80˚C. Age and sex-matched cortical tissue was kindly provided by 
the biobank of Hospital San Juan de Deu (HSJD). Parent informed consent and ethical 
approval from (HSJD) were obtained.  
For the present study samples from the temporal cortex were used for RNA extraction 
(QIAGEN), cDNA synthesis and subsequent quantitative PCR analysis. 
 
3.2  Human Induced Pluripotent Stem Cells (hIPSCs) 
 
3.2.1 Cell lines 
Cortical neurons were obtained from hIPSCs. Five cell lines were used in this study: two 
from healthy controls and three derived from RTT patients. Two lines were derived from 
RTT female patients with known MeCP2 mutations: EMC23i (named as RF1, R306C) and 
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EMC24i (named as RF2, R255X) were kindly provided by Joost Gribnau (Erasmus Medical 
School, Rotterdam, Netherlands). The cell line Rett-male (RM) was derived from a male 
patient (Q83X) and was a gift of Professor Alysson Muotri (University of California, San 
Diego, USA). Two control hIPSCs lines were used from healthy donors: Ct1 was 
reprogrammed in lab of Luis Pereira de Almeida (Centro de Neurociências e Biologia 
Celular, Coimbra) and derived from a healthy female donor. Ct2 was kindly provided by 
TCLab (Évora) and was derived from a healthy male donor (Table 3-1).  
Patient-derived fibroblasts were reprogrammed using a protocol described by Warlich, 
fluorescence‐based lentiviral reprogramming, using the four human genes: OCT4, SOX2, 
C-MYC and KLF4 (Warlich et al., 2011).  
 
            Table 3-1 – Characterization of hIPSCs lines (F - Female; M - Male; y-years).  
 
  










Ct2 3 M No TCLab 




















All reagents to generate cortical neurons from patient and healthy control-derived 
hIPSCs are described in tables 3-2 and 3-3.  
 
Table 3-2 – Reagents for hIPSCs expansion and neuronal induction. 
Material Description Preparation Supplier 
Accutase 
Mixture of proteolytic and collagenolytic 
enzymes used for the detachment of 
cells and tissues. It was used to perform 
single-cell passaging of hIPSCs-derived 
neural precursors. 
Ready-to-use solution. 




It is an aminopolycarboxylic acid that 
acts as a hexadentate ("six-toothed") 
ligand and chelating agent. Used to 
passage cells. 
Prepared by mixing 500 μl 
of 0.5M of EDTA stock, 500 
ml of sterile PBS (Sigma®) 
and 0.9g of NaCl (Sigma®) 
to adjust osmolality. 
Sigma® 
FGF2 
Promotes proliferation of neural 
progenitors in rosettes. 
Aliquots (20 ng/ml) stored 
at -20˚C. Working solution, 
diluted in 0.5 ml N2B27. 
Supplemented medium at 
1:100. 
PeproTech 
Laminin ECM protein used as coating matrix. 
Slowly thawed at 4˚C and 
then diluted in sterile PBS 
(Sigma®), to a final 
concentration of 20 μg/ml. 
Sigma® 
LDN-193189 
Small molecule which inhibits BMP 
signalling, allowing ectoderm 
differentiation. 
Diluted in DMSO to final 
concentration of 10 mM. 
Stored at -20˚C. Working 
dilution: 100 µM solution in 
DMSO. Supplemented 





Commonly used substrate for supporting 
the growth and self-renewal of hIPSCs. 
Composed mainly of laminin, collagen IV, 
heparin sulfate proteoglycans, entactin 
and growth factors. 
Aliquoted and frozen at -
20˚C. 







Antibiotic mixture used in culture to 
prevent bacterial contaminations. 
PenStrep (P/S), 5.000 units 
of penicillin and 
5.000μg/ml of 







Buffer solution containing sodium 
phosphate, sodium chloride and, in 
some formulations, potassium chloride 
and potassium phosphate. The 
osmolality and ion concentrations of the 
solutions match those of the human 
body. 






Table 3-3 – Medium formulation for hIPSCs expansion and neuronal induction. 
Medium Description Preparation 
mTeSRTM 
Complete and defined serum-free 
medium, with high concentrations 
of bFGF, TGF-β, GABA, pipecolic 
acid, lithium chloride. mTeSRTM1 is 
not xeno-free as it contains bovine 
serum albumin. 
To prepare 500 ml of mTeSR1, 100 
ml of thawed mTeSRTM1 5X 
supplement was mixed with 400 
ml of mTeSRTM1 basal medium. 




medium generally used for 
neuronal differentiation. 
 
Composed by 50% (v/v) of N2 
medium and 50% (v/v) of B27 
medium.  
N2 medium:  242.5 ml of 
DMEM/F12, 250 µl of insulin 
(20μg/ml), 2.5 ml of P/S (1%), 4 ml 
glucose 10% and 2.5 ml N2 
supplement (1%)  
B27 medium: 241.25ml of 
Neurobasal, 5ml of B27 
supplement (2%), 2.5 ml of L-
Glutamine (1mM) and 1.25 µl of 
P/S (1%) and 5 ml of B27 (2x) 
supplement. All from Life 
Technologies. 
Washing Medium Thaw hIPSCs. 
250ml of washing medium: 
218.5ml of KO-DMEM (Life 
Technologies);  25ml of KO-SR (Life 
Technologies), 2.5ml of MEM non-
essential aminoacids (1%), 1,25ml 
of L-Glutamine (1mM), 250μl of β-
Mercaptoethanol (0.1mM) and 




3.2.3 Matrigel dish coating 
Matrigel® was diluted in cold DMEM/F12 (4˚C) (1:30) supplemented with PenStrep 
(1:100) and then used to coat the wells of a 6-well plate (1 ml per well of a 6-well plate). 
Poly-L-
ornithine 
Culture substrate that increases 
attachment of neural cells. 
Diluted in ddH2O to a final 
concentration of 1.5 mg/ml 
(100x), filtered, aliquoted 
and stored at -20˚C. 
Sigma® 
SB-431542 
Potent inhibitor of ALK5, ALK4 and ALK7, 
preventing differentiation to mesoderm. 
Diluted in DMSO to a final 
concentration of 10 mM. 
Stored at -20˚C.  






The plate was incubated for at least 3 hours at room temperature. After the incubation at 
room temperature, the plate was store at 4˚C until further use. Medium was removed 
prior to cell seeding. 
 
3.2.4 Laminin coating 
Plates were incubated with poly-L-ornithine (15 µg/ml) at 37˚C, for at least 4 hours. 
Next, poly-L-ornithine was removed and replaced by laminin solution (20µg/ml diluted in 
PBS) and incubated at 37˚C for at least 4 hours. Laminin solution was removed before cell 
plating. 
 
3.2.5 hIPSCs expansion 
Initially cells were thawed adding drop-by-drop 1 ml of pre-heated (37˚C) washing 
medium, transferring them into a tube with warm medium and then centrifuged for 5 
minutes at 120g. The supernatant was discarded and cells were resuspended in pre-
warmed mTeSRTM1 supplemented with PenStrep (1:150) and plated on Matrigel®-coated 
plates.  
Cells were expanded for a few passages with a splitting-ratio of 1:3. Passages were 
performed when colonies were reaching 80% confluency. Cell passaging was performed 
using an enzyme-free method. The cell culture medium was removed from the well and 
cells were washed once with 0.5mM EDTA, followed by an incubation for 3-5 minutes with 
1.0 ml of 0.5mM EDTA. Cells were scraped from the well using the tip of the pipette, 
resuspended in 1 mL of mTeSRTM1 supplemented with PenStrep and transferred to a 
FalconTM tube taking special care not to get single-cell suspension. During the expansion 
phase medium was changed every day.  
Cells were cryopreserved using also the non-enzymatic procedure to help detach cells. 
Cells were washed with 1 mL of 0.5mM EDTA per well and then incubated with the same 
volume of EDTA for 3-5 minutes. Cells were then carefully scraped using the tip of the 
pipette, resuspended in 1 mL of washing medium and transferred to a FalconTM tube and 
centrifuged at 120g for 5 minutes. The supernatant was discarded and the cells were 
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resuspended with freezing medium (10% DMSO in Knockout Serum Replacement – KO-SR 
- (Life Tecnhologies)). Resuspended cells were then transferred to a cryovial and placed in 
a Mr. Frosty at -80˚C over-night. After this, cells were placed in liquid nitrogen (Figure 3.1).  
 
3.2.6 Neuronal induction, the dual SMAD inhibition protocol 
Several protocols have been described to obtain neurons. The dual SMAD inhibition 
protocol has been shown to be the most efficient since it combines two small molecules 
that inhibit TGF and BMP signalling: SB-431542 and LDN-193189. This protocol has been 
designed to obtain cortical glutamatergic neurons (Shi et al., 2012).  
Cells were expanded and plated according to the protocol described above. Final 
plating was performed on 2 wells of one 6-well plate (1 well for Protein extraction and 1 
well to carry on the differentiation) and on 4 wells of a 12-well plate (for immunostaining 
checkpoints), all previously coated with Matrigel®. 
IPSCs were plated on Matrigel® coated plates (see section 3.2.3) and medium 
(mTeSRTM1) was changed every day until cells became confluent. On day 1, mTeSRTM1 was 
replaced by N2B27 medium supplemented with the small molecules, SB-431542 and LDN-
193189 (1:1000) (Shi et al., 2012) preventing differentiation into endoderm and mesoderm 
lineages. Until day 12 of neuronal induction, medium was changed every day and was 
supplemented with the small-molecules. At day 12, cells were split 1:3 using EDTA 
(0.5mM) and seeded on laminin-coated plates (see below section 3.2.4). Cells were plated 
with N2B27 medium supplemented with the small molecules for 24h and after this 
medium was changed every day using non-supplemented N2B27. 
Between days 12-17 of neuronal induction, the first neuronal rosettes appeared and 
at this point the N2B27 medium was supplement with 20ng/mL of FGF2 for 4 consecutive 
days. Between day 17-20 cells were again split using EDTA (0.5mM) and replated on 
laminin-coated plates.  
The last passage was performed around day 30, when the first neurons begin to 
accumulate at the periphery of the rosettes.  At this stage, cells were single-cell passaged 
using accutase and replated on laminin-coated plates at a density of 50.000 cells/cm2. Cells 
were plated on a glass coverslip coated with laminin and a total of 18 wells of 24-well plate 
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were used. Briefly, wells were washed twice with PBS. Then, 1 mL of accutase was added 
and plates were incubated for 5-10 minutes at 37˚C. Cells were resuspended in washing 
medium, transferred to a FalconTM tube and centrifuged at 120g for 5 minutes, at room 
temperature. The supernatant was discarded and the pellet resuspended in culture 
medium, N2B27.  
From day 30 on, cell medium was change every other day leaving 1/3 of the old 
medium in the well. After day 60, N2B27 was supplemented with laminin (1:200) once a 
week to promote and maintain cell adherence to the glass coverslip (Figure 3.1). 
We have generated cortical neurons from all the hIPSCs lines. In the case of RM and 
RF1 two independent rounds of differentiation were performed, referred to as RM-1, RM-




Figure 3.1 - Schematic representation of neuronal differentiation, described in sections 3.2.5 and 3.2.6. 
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3.3  Molecular Biology Techniques 
 
3.3.1 Western-Blot analysis 
 
Protein Extraction 
Protein extracts for Western-Blot analysis were prepared from snap-frozen mice cortex 
and from differentiated neurons-derived from hIPSCs (day 120).  
Neurons-derived from IPSCs. Cells were washed with iced-cold PBS and lysed with 
radio-immunoprecipitation assay (RIPA) buffer: 50mM Tris-HCl (pH 7.5), 150mM NaCl, 
5mM ethylenediamine tetra-acetic acid (EDTA), 0.1% SDS and 1%Triton X-100 and 
protease inhibitors cocktail (Mini-Complete EDTA-free; Roche Applied Science).  
Mouse cortex. Snap-frozen cortex samples were first disrupted with a Teflon pestle in 
50 mM sucrose-Tris (pH 7.6) supplemented with protease inhibitors cocktail (Mini-
Complete EDTA-free; Roche Applied Science). 
All lysates were then vortexed and sonicated (3 cycles of 15 seconds), and clarified by 
centrifugation (13000g, 10min). The protein content in the supernatant was determined 
by Bio-Rad DC reagent, a commercial Bradford assay (Sigma®). 
 
Protein Electrophoresis, Transfer and Detection/Quantification 
Equal amounts of protein were loaded (neuron-derived from hIPSCs: 30-45 µg; mice 
cortices: 70 µg except for A2AR blot: 200 µg) and separated on 10% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to 
polyvinylidene fluoride (PVDF) membrane (GE Healthcare). To check protein transfer 
efficiency, membranes were stained with Ponceau S solution. After blocking with a 5% 
non-fat dry milk solution in TBS-T (20 mM Tris base, 137 mM NaCl and 0.1% Tween-20), 
membranes were washed three times with TBS-T, before incubation with the primary 
antibody, diluted in 3% BSA solution in TBS-T (overnight at 4˚C) and secondary antibodies 
diluted in blocking solution (1 hour at room temperature).  
Immunoreactivity was visualized using ECL chemiluminescence detection system 
(Amersham-ECL Western Blotting Detection Reagents from GE Healthcare) and band 
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intensities were quantified by digital densitometry (ImageJ 1.45 software). α-tubulin or β-
actin bands were used as loading control.   
 
Antibodies  





           Table 3-5 – Western-Blot secondary antibodies. 
 
 
Protein Primary Antibody Dilution Supplier 
A2AR A2AR 1:1500 






Kindly provided by 





















1:3000 Abcam® (ab4074) 
Secondary Antibody Dilution Supplier 
Goat anti-mouse IgG-HRP 1:10000 
Santa Cruz Biotechnology 
(sc-2005) 
Goat anti-rabbit IgG-HRP 1:10000 




3.3.2 ELISA assay 
To determine BDNF protein concentration in mice hippocampi and in neurons-derived 
from hIPSCs, ELISA assays using BDNF Emax® ImmunoAssay System (Promega, USA) were 
performed. 
Lysates were prepared with 200 µl of lysis buffer (137mM NaCl; 20mM Tris-HCl (pH 
8.0); 1% NP40; 10% glycerol; 1mM PMSF; 10μg/ml aprotinin; 1μg/ml leupeptin; 0.5mM 
sodium vanadate) and homogenised in a sonicator (Vibra-Cell, Sonics & Materials, Inc). 
RIPA buffer (described in section 3.3.1) was used to prepare the protein lysates from 
neurons-derived from hIPSCs. To improve BDNF detection, samples were acidified with 
HCl 1M, until reaching approximately pH 2.6. After 10 to 20 minutes NaOH was added to 
neutralise samples to 7.6 pH. 
Nunc-Immuno™ MaxiSorp™ plates were used to execute the technique and all steps 
were done according to manufacturer’s instructions. 
 
3.3.3 Immunohistochemistry 
Immunohistochemistry was only performed with hIPSCs-derived neurons in order to 
follow their neuronal differentiation, using appropriate cell-type specific markers (section 
4.3.2). Cells were washed with PBS and fixed with 2% paraformaldehyde (PFA) during 1 
hour, followed by 5minutes incubation with methanol. Cellular permeabilization and 
blocking were performed using 10% fetal bovine serum (FBS) with 0.1% Triton in PBS 
(Sigma®) for 30 minutes. Primary antibodies were diluted in blocking solution and 
incubated overnight at 4˚C. Cells were then washed three times for 5 minutes with TBS-T 
(described in section 3.3.1). Secondary antibodies were diluted in blocking solution and 
cells were incubated for 1 hour at room temperature. After secondary antibody incubation 
cells were washed three times in TBS-T and DAPI (1:1000 dilution in PBS; Sigma®) 
counterstaining was used to label the nucleus for 10 minutes. Cells were mounted with 







Table 3-6 – Immunohistochemistry primary antibodies. 
 
 




























































1:600 Santa-Cruz (sc-49574) 
VGLUT 








1:200 Zymed  (33-9100) 
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Table 3-7 – Immunohistochemistry secondary antibodies. 
 
 
3.3.4 RNA extraction and cDNA synthesis 
 
Mouse Tissue 
Total RNA was extracted from mice cortices, using RNeasy Lipid Tissue Mini Quit 
(Qiagen), according to the manufacturer’s instructions. RNA concentration and purity was 
then evaluated by spectrophotometry based on optical density (OD), measurements at 
260 and 280 mm (Model: NanoDrop-100; Thermo Scientific).  
cDNA synthesis was performed in a 20µl reaction mixture. 2 µg of total RNA were 
mixed with 1 µl random primer hexamers (Amersham) and 1 µl each of dATP, dTTP, dCTP 
and dGTP (10 mM). This mix was incubated 5 minutes at 65˚C and after cooling for 2 
minutes on ice, the remaining reagents were added (4 µl of 25 mM MgCl2, 2 µl of 10x RT 
buffer, 2 µl of 0.1M DTT, 0.5 µl Superscript II Reverse Transcriptase (200U), all reagents 
from Invitrogen, Life Technologies). The reaction was incubated for 50 minutes at 42˚C and 
followed by 15 minutes incubation at 70˚C to inactivate the enzyme. Parallel reactions for 
Secondary Antibody Dilution Supplier 
Donkey anti-goat, Alexa F594 1:400 
Molecular Probes 
(A11056) 





Donkey anti-rat, Alexa F488 1:400 
Molecular Probes 
(A21208) 
Goat anti-mouse, Alexa F488 1:400 
Molecular Probes 
(A11001) 
Goat anti-rabbit, Alexa F594 1:400 
Molecular Probes 
(A11012) 
Goat anti-rabbit, Alexa F647 1:400 
Molecular Probes 
(A21244) 





each RNA sample were run without Superscript II to evaluate the degree of genomic DNA 
contamination. Completed reverse transcription (RT) reactions were stored at -20˚C until 
further used. 
 
Neurons-derived from IPSCs and human brain tissue 
A similar protocol was followed for RNA extraction and cDNA synthesis from neurons-
derived from hIPSCs and human brain tissue, being described in this section the 
differences between them. RNeasy Mini Kit (QIAGEN) was used for total RNA isolation with 
DNase digestion on the column, to avoid DNA contamination, according to manufacturer’s 
instructions. cDNA synthesis was performed with 0.5 µg of total RNA and the second mix 
was composed by 4 µl of 5x First-Strand Band Buffer, 2 µl of 0.1 DTT, 1 µl of RNase Out (40 
units/µl) and 1 µl of Superscript II RT (all reagents from Invitrogen). Reaction mix was first 
incubated for 10 minutes at 25˚C followed by 50 minutes at 42˚C. 
 
3.3.5 Quantitative PCR  
 
Mouse Tissue 
Gene expression level was addressed by quantitative PCR (qPCR) using Power SYBR® 
Green Master Mix (Life Technologies), and cDNA was used as template for the real-time 
PCR run in Rotor Gene 6000 (Corbett Life Science). The thermal cycler conditions were as 
follows: hold for 10 minutes at 95°C, followed by 40 cycles of a two-step PCR consisting of 
a 95°C step for 15 seconds followed by a 60°C step for 25 seconds. A final thermal ramp 
from 72 to 95 degrees was performed in each experiment. Negative control PCR samples 
were run with no template. Relative mRNA expression was calculated using 2-Δct method 
and primers were previously optimized in order to establish annealing temperature and 
primer efficiency (e=2±0.2), calculated after serial primer dilutions and  construction of 
respective standard curve (slope and R2 respectively around -3.3 and 0.99 described in 
Schmittgen and Livak 2008). Data were normalized to the expression of PPIA peptidylprolyl 
isomerase A (cyclophilin A) (CypA) and ribosomal protein L13A (Rpl13A). Data acquisition 
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was performed with Rotor-Gene Series Software 1.7 (Corbett Life Science) and data 
analysis was performed with Microsoft Excel. 
 
Neurons-derived from IPSCs and human brain tissue 
Once again, the qPCR protocol was similar to the above described, being here 
mentioned the different steps. The real time-PCR was run in 7500 Fast (Applied 
Biosystems), with the same thermal cycler conditions as the described above, taking into 
account the annealing temperature for the primers used (Schmittgen and Livak, 2008). The 
normalization was done to GAPDH expression. Data acquisition was performed with 7500 
software v2.0.6 (Applied Biosystems) and data analysis was performed in Microsoft Excel. 
 
 Primers 
Table 3-8 – Primer sequence and annealing temperature for all primer pairs used for quantitative analysis. 


















ATT CCA CTC CGG 
TAC AAT GG 
AGT TGT TCC AGC 




TCG GCT GGC TAC 
CAC CCC TTG 
CCA GCA CCC AAG 





GAG CTG CTG ACC 
AAC CTC CA 
GTC CCC GTG CTT 





TAA GAT CCC CCT 
GGA TGG GTA G 
AAG CAG CAC TTC 







TAT CTG CAC TGC 
CAA GAC TGA GTG 
CTT CTT GCT GGT 





GGA TCC CTC CAC 
CCT ATG ACA 
CTG GTA CTT CCA 









GCC ACA GAC CTA 
CTT CCA CA 
CCT TCT CGA ACT 





AAC CTG CAG AAC 
GTC AC 
GTC ACC AAG CCA 





GGC CCA GAT GCT 
GTC ATT AT 
TGC CTT TTG GTA 




Note: Primers were stocked at 100 µM and frozen at -20˚C. 0.4 µl of each primer were added for real-time PCR run, except for GFAP and 
MAP2 run where was added 0.2 µl 
 
3.4  Electrophysiology  
 
3.4.1 Ex vivo electrophysiological recordings 
 
Hippocampus isolation and slice preparation 
 The animals were first anesthetized with isoflurane (1,2-Propylenglycol 50% (v/v)) in 
an anaesthesia chamber. When animals showed the first signs of anaesthesia state, like 
reduction of respiratory rate and lack of reflexes, they were sacrificed by decapitation. In 
order to have access to the brain, the skull was exposed by cutting the skin at the top of 
the head and then the brain was carefully removed and placed in ice-cold artificial 
cerebrospinal fluid (aCSF – Krebs’ solution) containing: 124 mM NaCl; 3 mM KCl; 1.25 mM 
NaH2PO4, 26 mM NaHCO3, 1 mM MgSO4, 2 mM CaCl2 and 10 mM glucose previously gassed 
with 95% O2 and 5% CO2, pH 7.4. The two brain hemispheres were separated through the 
midline and the hippocampus was isolated, taking care not to damage it with the spatulas. 
When isolated, the hippocampus was cut perpendicularly to the long axis into slices with 




TCT ATG CTG TGG 
TGG TGA TTG 
GAG TCC AGC TTA 






TAA CGG CGG CAG 
ACA AAA AGA 
GAA GTA TTG CTT 






CAC GGA AGC TTA 
AGC AAA GG 
CCC TCG GTG TTT 






GGA GTC AAC GGA 
TTT GGT CG 
GAC AAG CTT CCC 





TGC TCG CCG CTC 
CTA CGT CT 
ATC CAC CCG GGT 






CTG CTC GTG TAG 
TGG ACG AA 
CGA TCT CAT TGC 





CGT GAT GAC CTC 
CTT GGT CT 
CAA GAA GTT CCC 




chamber in Krebs’ solution permanently oxygenated at room temperature for one hour in 
order to recover.  
 
Basal synaptic transmission 
After functional and energetic recovery, slices were transferred to the recording 
chamber for submerged slices, being continuously superfused with bathing solution 
(Krebs’ solution) gassed with 95% O2 and 5% CO2 at 32˚C. The flux of bathing solution was 
established at 3ml/min and the drugs used were added to this superfusion solution. 
Recordings were obtained with Axoclamp 2B amplifier and digitized (Axon 
Instruments, Foster City, CA). Individual responses were monitored and averages of eight 
consecutive responses were continuously store on personal computer with LTP program 
(Anderson and Collingridge, 2001). Field excitatory post-synaptic potentials (fEPSPs) were 
recorded through an extracellular microelectrode (2-8 MW resistance, Harvard apparatus 
LTD, Fircroft way, Edenbridge, Kent) placed in the stratum radiatum of the CA1 area 
(Figure 3.4 a)). Stimulation (rectangular 0.1 ms pulses, once every 15 seconds) was 
delivered through a concentric electrode placed on the Schaffer collateral-commissural 
fibers, in the stratum radiatum near CA3-CA1 border. The stimulus intensity (80-200 µA) 
was initially adjusted to obtain a large fEPSP with a minimum population spike 
contamination (Figure 3.4 b)).  
Alteration on synaptic transmission was evaluated as the % change in the average 
slope of the fEPSP in relation to the average slope of the fEPSP measured during the 10 
minutes preceded the addiction of the drugs used in the experiment (baseline), as 
previously described (Diógenes et al., 2004).  
a) b) 
Figure 3.2 - Extracellular recording from hippocampal slices. a) Represents the stimulation of one set of 
the Shaffer collateral-commissural pathway (S1) in a hippocampal slice to record extracellular responses in 
the CA1 dendritic layer (stratum radiatum). b) Representative tracing obtained, composed by 1 - stimulus 
artefact, followed by 2 - presynaptic volley and 3 – the field excitatory postsynaptic potentials (fEPSP)  






Table 3-9 – Drugs used in electrophysiology. 
Note: All drugs mentioned were aliquoted as stock solutions of 5mM (DPCPX) and 50 mM (ITU) and stored at -20ºC. 
 
 
3.5 Data analysis 
The values are presented in mean ± SEM of n number of independent experiments. 
Statistical significance was evaluated using non-paired Student’s t-test. A p-value˂0.05 
represents differences that are statistically significant. Prism GraphPad software was used 
























Tocris (Natick, MA, 
USA) 
ITU 5-iodotubercidin ADK inhibitor 100 nM 








Figure 4.1 – BDNF signalling througt TrkB receptors.BDNF binding to TrkB promotes its phosphorylation 
and dimerization. This phosphorylation in various sites can activate downstream pathways such as: PI3K 
pathway activates AKT, leading to cell survival. The MAPK/ERK pathway leads to cell growth and 
differentiation. The PLCγ pathway activates IP3 receptor to release intracellular calcium stores leading to 
enhanced CamK activity, leading to synaptic plasticity. All three pathways converge on transcription factor 
CREB, which can up-regulate gene expression. AKT - protein kinase B; CamK - calmodulin kinase; CREB - 
cAMP response element binding protein; DAG, - diacylglycerol; ERK - Extracellular signal-regulated kinases; 
IP3 - inositol 1,4,5-trisphosphate; MAPK - mitogen-activated protein kinases; PI3K - phosphatidylinositol 3-
kinase; PLC – phospholipase C (adapted from Autry & Monteggia 2012) 
 
Figure 4.2 – A1R mRNA expression and protein levels. a) Histogram represents relative qPCR data showing 
mRNA levels of A1R present in cortical samples of WT (white bars, n=5) and Mecp2 KO (black bars, n=5). 
PPIA and RPL13A were used as internal loading controls. b) Graphic shows saturation isotherms for the 
binding of the selective A1R receptor antagonist [H3]DPCPX to the cortical homogenates of WT (circles, n=5) 
and Mecp2 KO (triangles, n=5) mice. All values are mean ± standard error of mean (SEM). (Binding assay 
were performed and described in Cátia Palminha master thesis)Figure 4.2 – BDNF signalling througt TrkB 
receptors.BDNF binding to TrkB promotes its phosphorylation and dimerization. This phosphorylation in 
various sites can activate downstream pathways such as: PI3K pathway activates AKT, leading to cell 
survival. The MAPK/ERK pathway leads to cell growth and differentiation. The PLCγ pathway activates IP3 
receptor to release intracellular calcium stores leading to enhanced CamK activity, leading to synaptic 
plasticity. All three pathways converge on transcription factor CREB, which can up-regulate gene expression. 
AKT - protein kinase B; CamK - calmodulin kinase; CREB - cAMP response element binding protein; DAG, - 
diacylglycerol; ERK - Extracellular signal-regulated kinases; IP3 - inositol 1,4,5-trisphosphate; MAPK - 
mitogen-activated protein kinases; PI3K - phosphatidylinositol 3-kinase; PLC – phospholipase C (adapted 
from Autry & Monteggia 2012) 
4. Results 
 
4.1 Characterization of adenosine receptors in Mecp2 KO mice model 
 
This thesis was developed within a broader project that includes one PhD student (Sofia 
Duarte, co-supervisor of the present study) and another Master student (Cátia Palminha). 
Therefore, and for the sake of clarity, some of the here presented results were obtained 
by the above mentioned students and are clearly acknowledged throughout the thesis. 
 
4.1.1 Rational 
As described in section 1.3.3 of this manuscript, adenosine receptors alterations have 
already been reported in multiple disorders, some of them sharing common features with 
RTT. However, the adenosinergic system has never been explored in RTT. Then, our lab 
started to investigate this topic in order to understand whether changes in adenosinergic 
system, in RTT, could contribute to RTT pathophysiology.  
Results obtained by Cátia Palminha (Palminha, 2014) suggest that hippocampal 
adenosine levels might be decreased in Mecp2 KO mice when compared with WT mice. 
Extracellular adenosine levels were studied by evaluating indirectly the disinhibition of 
synaptic transmission, caused by the selective A1R antagonist, DPCPX (Figure 4.1 a) 
adapted from Palminha, 2014). Hippocampal slices from Mecp2 KO mice showed a smaller 
disinhibition caused by DPCPX, which probably indicates that Mecp2 KO mice have lower 
levels of endogenous adenosine or decreased levels of A1AR. To corroborate this 
hypothesis, synaptic transmission was also studied with de A1R agonist, CPA. CPA causes 
a lower inhibitory effect upon synaptic transmission when endogenous levels of adenosine 
are higher or when A1AR levels are decreased. Testing progressively higher CPA 
concentrations, the inhibitory effect was significantly more pronounced in hippocampal 
slices taken from Mecp2 KO mice, indicating the possibility of the presence of lower levels 
of endogenous adenosine or/and higher levels of A1AR levels  (Figure 4.1 b) adapted from 
Palminha, 2014). Taken together, these data strongly suggest an impairment on 
endogenous levels of adenosine. As a consequence, inefficient activation of both A2AR and 
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A1R might occur. Given the important role of A2AR on BDNF levels (Tebano et al., 2008) and 
on its synaptic activity (Fontinha et al., 2008; Diógenes et al., 2004) an impairment of 
endogenous A2AR activations could drastically compromise BDNF mediated signalling. 
Furthermore, impairment of the inhibitory A1R activation could promote excitability 
(epilepsy).   
 Moreover, changes in adenosine receptors were also detected. Binding protein assays 
showed increased A1R protein expression level in Mecp2 KO mice when compared to WT 
animals (Figure 4.2, adapted from (Palminha, 2014)). Therefore, the following experiments 








Figure 4.2 - A1R protein expression level in Mecp2 KO mice. Graphic shows saturation isotherms for the 
binding of the selective A1R receptor antagonist [H3]DPCPX to the cortical homogenates of WT (circles, n=5) 
and Mecp2 KO (triangles, n=5) mice. Values are presented in mean ± SEM. # p-value˂0.05 (F test) (Binding 
assays were performed and described in Cátia Palminha master thesis (Palminha, 2014)).  
 
a) b) 
Figure 4.1 - Changes in fEPSP induced by DPCPX and CPA. a) averaged time course of changes in fEPSPs 
slope induced by application of DPCPX (50 nM) for 40 minutes and b) averaged time course of changes in 
fEPSP slope induced by application of three different concentrations of CPA (3 nM, 10 nM and 30 nM) for 
120 minutes. WT (black symbols, n=4;7) and Mecp2 KO (blue symbols, n=8;7). The ordinates represent 
normalised fEPSP slopes, where 0% corresponds to the average slopes recorded 10 minutes before 
DPCPX/CPA application and the abscissa represents recording time in minutes. Adapted from Cátia 




4.1.2 Adenosine receptors changes in Mecp2 KO mice 
To better understand how the adenosinergic system was altered in the RTT animal 
model, the cortical A1R and A2AR mRNA expression and protein levels were evaluated.  
As seen in Figure 4.3, A1R mRNA relative expression showed no statistically significant 
difference between both genotypes (WT: 0.030 ± 0.0036, n=5 and Mecp2 KO: 0.025 ± 
0.0040, n=5).  
 
In parallel, the analysis of A2AR mRNA relative expression also revealed no statistically 
significant differences (Figure 4.4 a)) between genotypes (Mecp2 KO: 0.030 ± 0.005, n=5 
and WT: 0.020 ± 0.006, n=5). Interestingly, Western-Blot analysis of cortical homogenates 
shows a significant decrease (Figure 4.4 b); p-value˂0.05) of A2AR protein expression level 
in cortical samples from Mecp2 KO mice (37.52% ± 11.30, n=6) when compared to WT 
(100% ± 24.80, n=6).  
Figure 4.3 - A1R mRNA relative expression in Mecp2 KO mice. A1R mRNA expression level evaluated by 
qPCR in cortical samples of WT (white bars, n=5) and Mecp2 KO (black bars, n=5). PPIA and RPL13A were 






Figure 4.4 - A2AR mRNA relative expression and protein expression level in Mecp2 KO mice. a) Relative qPCR 
data showing A2AR mRNA relative expression in cortical samples of WT (white bars, n=5) and Mecp2 KO (black 
bars, n=5). PPIA and RPL13A were used as internal controls. b1) representative Western-Blot of WT and 
Mecp2 KO mice, using primary antibody against A2AR (~45 kDa) and α-tubulin (~55 kDa), used as loading 
control. These bands were detected from cortical homogenates of WT (white bars, n=6) and Mecp2 KO (black 
bars, n=6) mice. b2) Quantification of A2AR immunoreactivity obtained by Western-Blot analysis. 






















Figure 4.7 – BDNF signalling througt TrkB receptors.BDNF binding to TrkB promotes its phosphorylation 
and dimerization. This phosphorylation in various sites can activate downstream pathways such as: PI3K 
pathway activates AKT, leading to cell survival. The MAPK/ERK pathway leads to cell growth and 
differentiation. The PLCγ pathway activates IP3 receptor to release intracellular calcium stores leading to 
enhanced CamK activity, leading to synaptic plasticity. All three pathways converge on transcription factor 
CREB, which can up-regulate gene expression. AKT - protein kinase B; CamK - calmodulin kinase; CREB - 
cAMP response element binding protein; DAG, - diacylglycerol; ERK - Extracellular signal-regulated kinases; 
IP3 - inositol 1,4,5-trisphosphate; MAPK - mitogen-activated protein kinases; PI3K - phosphatidylinositol 3-
kinase; PLC – phospholipase C (adapted from Autry & Monteggia 2012) 
 
Figure 4.2 – A1R mRNA expression and protein levels. a) Histogram represents relative qPCR data showing 
mRNA levels of A1R present in cortical samples of WT (white bars, n=5) and Mecp2 KO (black bars, n=5). 
PPIA and RPL13A were used as internal loading controls. b) Graphic shows saturation isotherms for the 
binding of the selective A1R receptor antagonist [H3]DPCPX to the cortical homogenates of WT (circles, n=5) 
and Mecp2 KO (triangles, n=5) mice. All values are mean ± standard error of mean (SEM). (Binding assay 
were performed and described in Cátia Palminha master thesis)Figure 4.8 – BDNF signalling througt TrkB 
receptors.BDNF binding to TrkB promotes its phosphorylation and dimerization. This phosphorylation in 
various sites can activate downstream pathways such as: PI3K pathway activates AKT, leading to cell 
survival. The MAPK/ERK pathway leads to cell growth and differentiation. The PLCγ pathway activates IP3 
receptor to release intracellular calcium stores leading to enhanced CamK activity, leading to synaptic 
plasticity. All three pathways converge on transcription factor CREB, which can up-regulate gene expression. 
AKT - protein kinase B; CamK - calmodulin kinase; CREB - cAMP response element binding protein; DAG, - 
diacylglycerol; ERK - Extracellular signal-regulated kinases; IP3 - inositol 1,4,5-trisphosphate; MAPK - 
mitogen-activated protein kinases; PI3K - phosphatidylinositol 3-kinase; PLC – phospholipase C (adapted 
from Autry & Monteggia 2012) 
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4.1.3 Adenosine kinase as a possible cause of adenosine impairment in 
Mecp2 KO mice 
 ADK evaluation 
As already mentioned in section 1.3.1, together with ADA, ADK is responsible for the 
degradation of adenosine in order to maintain its endogenous concentration within 
homeostatic levels (Boison, 2013). Changes in this enzyme have already been associated 
to multiple disorders, such as epilepsy (Gouder et al., 2004; Boison, 2012; Boison, 2013; 
Aronica et al., 2013). In particular, ADK levels are increased in epileptic mouse models and 
also in the human epileptic brain (Aronica et al., 2013), which leads to lower endogenous 
adenosine level and consequently a lower inhibition of synaptic transmission (Boison, 
2013). Previous data from the lab points to a decrease of endogenous adenosine level in 
RTT mice model (Palminha, 2014), thus the possibility that changes in ADK could be 
involved was raised. Therefore, ADK protein expression level was evaluated by Western-
Blot, and as shown in Figure 4.5, there was no significant differences between Mecp2 KO 
(121.5% ± 10.13, n=8) and WT (100.2 %± 3.611 n=8) mice.  
 
Figure 4.5 - ADK protein expression level in Mecp2 KO mice. a1) Representative Western-Blot of cortical 
tissue homogenates from Mecp2 KO and WT mice. Primary antibodies used recognize ADK isoforms (~40 
kDa) and α-tubulin (~55 kDa), used as loading control. a2) average band intensity for ADK obtained from 
WT (white bars, n=8) and Mecp2 KO (black bars, n=8) cortical homogenates by Western-Blot analysis. All 

















Although no significant alterations in ADK protein expression level have been detected, 
the evaluation of ADK function was considered to be a critical aspect to take into account. 
Therefore, ADK function was, indirectly, evaluated by studying the effect of the ADK 
inhibitor, iodotubercidin (ITU) (Pak et al., 1994) upon synaptic transmission.  ITU, by 
blocking ADK activity, increases adenosine levels promoting inhibition of synaptic 
transmission through A1R activation. Therefore, the higher the activity of ADK, the lower 
the level of adenosine and as a consequence the higher the inhibition of synaptic 
transmission induced by ITU. Thus, if a higher activity of ADK was the cause of the reduced 
adenosine level in RTT, the ITU should induce a higher inhibition of synaptic transmission 
in hippocampal slices taken from Mecp2 KO mice. However this might not be the case. 
Hippocampal slices were superfused by Krebs’ solution containing ITU (100 nM) by 84 
minutes as described before (Diógenes et al. 2004).  As shown in Figure 4.6, ITU caused a 
similar decrease on synaptic transmission in hippocampal slices from the two genotypes 
(WT: approximately 48% inhibition, n=7; Mecp2 KO: approx. 38% inhibition, n=2). 
Interestingly, the superfusion of the same slices with the selective A1AR antagonist, DPCPX 
(50 nM), caused a more pronounced disinhibition of synaptic transmission in hippocampal 
slices taken from WT animals (WT: approx. 50% desinhibition, n=7; Mecp2 KO: approx. 
10% desinhibition, n=2). Although it is indispensable to increase the number of 
experiments, this data corroborate the hypothesis that endogenous adenosine level might 











































































































































Figure 4.6 - fEPSP changes induced by ITU and ITU+DPCPX. Graphic shows the averaged time course of 
changes in fEPSP slope induced by ITU (100 nM) applied for 84 minutes followed by ITU (100 nM) + DPCPX 
(50 nM) for 60 minutes. Hippocampal slices were taken from WT (white circle, n=7) and Mecp2 KO mice 
(black circle, n=2). Ordinate axis represents normalised fEPSP slopes, where 0% corresponds to the averaged 
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4.2 BDNF signalling impairment in Mecp2 KO mice  
 
4.2.1 Rational 
 BDNF, through TrkB-FL receptor activation, regulates neuronal survival, differentiation 
and synaptic plasticity (Huang and Reichardt, 2003) such as LTP, the neurophysiological 
basis for learning and memory (Bliss and Collingridge, 1993). It has been postulated that 
BDNF level is decreased in RTT (reviewed by Li and Pozzo-Miller, 2014) however less 
attention has been given to TrkB receptors. Recently, data from our lab (Duarte, 2015 in 
preparation) clearly demonstrated that the well-known facilitatory effect of exogenous 
BDNF upon hippocampal LTP is completely lost in hippocampal slices taken from Mecp2 
KO. This data strongly suggest that together with the lower endogenous BDNF level, also 
the BDNF receptors could be affected. Indeed, recent data clearly show a significant 
decrease on TrkB-FL receptors in the hippocampus of Mecp2 KO when compared to WT 
animals (Figure 4.7 a), Duarte, 2015 in preparation). No significant alterations were 







Figure 4.7 - TrkB-FL and TrkB-Tc protein expression level in Mecp2 KO mice. a1) Representative Western-
Blot of cortical tissue homogenates from Mecp2 KO and WT mice. Primary antibodies used recognize TrkB-
FL (~140 kDa) and GAPDH (~36kDa), used as loading control. a2) average band intensity for TrkB-FL 
obtained from WT (white bars, n=10) and Mecp2 KO (black bars, n=8) cortical homogenates by Western-
Blot. Values obtained for WT samples in Western-Blot are considered as 1. All values presented are mean 
± SEM. *p-value˂0.05 (Student’s t-test). b1) Representative Western-Blot of cortical tissue homogenates 
from Mecp2 KO and WT mice. Primary antibodies used recognize TrkB-Tc (~95 kDa) and β-actin (~42kDa), 
used as loading control. b2) average band intensity of TrkB-Tc obtained from WT (white bars, n=10) and 
Mecp2 KO (black bars, n=8) cortical homogenates by Western-Blot analysis. Values obtained for WT 




In order to provide more detailed information about BDNF signalling, this chapter was 
devoted to the evaluation of TrkB mRNA expression and to the determination of BDNF 
protein expression level in this RTT animal model. Regarding to TrkB mRNA expression 
evaluation, only TrkB-T1 truncated isoform was studied, once this truncated isoform is the 
most abundant and well characterized in human/mice brain. 
 
4.2.2 BDNF protein expression level in Mecp2 KO mice 
 BDNF protein expression level was evaluated as described in methods section by ELISA 
assays. As expected, the results reveal a significant decrease (p-value˂0.05) in BDNF 
protein expression level in homogenates prepared from Mecp2 KO mice cortex when 
compared to samples from WT animals (Mecp2 KO: 0.491 pg/mg ± 0.167, n=3; WT: 2.237 
pg/mg ± 0.385, n=4; Figure 4.8).  
 
4.2.3 TrkB receptors characterization in Mecp2 KO mice 
 Both TrkB-FL and TrkB-T1 mRNA relative expression were analysed by qPCR as 
described in the methods section. As shown in Figure 4.9 a) there are no significant 
differences between WT (0.123 ± 0.026, n=5) and Mecp2 KO mice (0.180 ± 0.033, n=5). 
Regarding TrkB-T1 mRNA expression, no significant changes were detected between 
Mecp2 KO (0.222 ± 0.026, n=5) and WT mice (0.178 ± 0.026, n=5) (Figure 4.9 b)). 
 
 
Figure 4.8 - BDNF concentration in Mecp2 KO mice. BDNF concentration (pg/mg), evaluated by ELISA assay, 
in cortical homogenates from WT (white bars, n=4) and Mecp2 KO (black bars, n=3) mice. All values are 











Figure 4.9 - TrkB-FL and TrkB-T1 mRNA relative expression in Mecp2 KO mice. TrkB-FL (a)) and TrkB-T1 (b)) 
mRNA expression level evaluated by qPCR in cortical samples of WT (white bars, n=5) and Mecp2 KO (black 
bars, n=5). PPIA and RPL13A were used as internal loading controls. All values presented are mean ± SEM.  
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4.3 Exploring adenosinergic system through neurons-derived from hIPSCs 
and in human brain sample 
 
4.3.1 Rational 
Mouse models are widely chosen to study RTT, in particular Mecp2 KO mice. Like any 
model, it has benefits but also some limitations (discussed in section 1.2). Therefore, it is 
important to study more than one model to increase the likelihood of finding something 
relevant. Neurons-derived from hIPSCs have been recently used to model diseases, and 
offer the opportunity to compare, “in vitro”, neurons-derived from RTT patients and 
healthy controls.  
In this chapter, mRNA expression of adenosine receptors, BDNF and TrkB receptors will 
be studied and were quantified in neurons-derived from hIPSCs and in human brain 
sample. Protein expression level of TrkB receptors and BDNF will be also studied and were 
quantified only in neurons-derived from hIPSCs. 
 
4.3.2 Characterization of hIPSCs 
One crucial aspect that must be considered before using in vitro differentiated cortical 
neurons is to validate their identity. IPSCs are multipotent and able to differentiate into 
any of the 3 embryonic lineages: endoderm, mesoderm and ectoderm. Although, the dual 
SMAD inhibition protocol is quite efficient in directing cells along the neuroectoderm 
differentiation cascade, while inhibiting endodermal and mesodermal lineages, we have 
still to guarantee that the generated neuroprogenitors have anterior identity. Throughout 
neuronal differentiation several well-characterized stages can be identified by the 
expression of a set of proteins (Table 4-1). Immunofluorescence of these cell-type specific 






Table 4-1 - Neuronal markers used to characterize hIPSCs. (Shi et al., 2012; Adams et al., 2007; Molyneaux et 
al., 2007; Thompson et al., 2005). 
Marker Expression Description 
OCT3/4 Pluripotent stem cells 
Belongs to the core pluripotency network responsible for 
maintaining self-renewal and undifferentiated embryonic stem 
cells. 
SOX2 
Neuronal stem cells  and 
neuronal progenitors 
Expressed by developing cells from the neural tube and in neural 
progenitors in the CNS, being inactivated upon terminal 
differentiation. 
PAX6 
Neuronal stem cells and 
neuronal progenitors 
Expressed in human neuroectoderm cells. Key role in the onset of 
human neuroectoderm differentiation into any region-specific 
neural progenitors. 
OTX2 
Neuronal Stem cells and 
neuronal progenitors 
Expressed throughout the forebrain and midbrain, being an 
excellent marker of anterior specification. 
FOXG1 Neuronal progenitors Expressed only in the anterior neuroectoderm. 
ZO1 Neuronal progenitors 




and early neurons 
Intermediate filament protein type VI, expressed in neuronal 
progenitors. 
GFAP Astrocytes Intermediate filament protein expressed in astrocytes. 
TUJ1 
Postmitotic neurons and 
differentiated neurons 
Belong to the tubulin protein family and is exclusively expressed 
in neurons. 
TBR1 
Early neurons and deep-
layer neurons 
Regulates cortical development, specifically within layer VI of the 
human cortex. 
TBR2 Early neurons Expressed in basal neural progenitors. 
BRN2 
Progenitor cells and 
deep-layer neurons 
Marker of human cortical layer II/III and V. 
CTIP2 Deep-layer neurons 
Expressed in deep-layer neurons with higher expression levels in 
subcerebral neurons of layer V. 
MAP2 
Early neurons and 
differentiated neurons 
Belongs to the tubulin protein family and is exclusively expressed 
in neurons. 
SNAP25 Presynaptic density 
SNAP-25 is a component of the trans-SNARE complex, responsible 
for forming a tight complex that brings the synaptic vesicle and 
plasma membranes together. 
VGAT GABAergic neurons 
Integral membrane protein involved in gamma-aminobutyric acid 
(GABA) and glycine uptake into synaptic vesicles. 
VGLUT Glutamatergic neurons 
Responsible for the uptake of the excitatory amino acid, L-




As expected, OCT3/4, expression is not detected at day 12 indicating that all cells have 
been able to exit into differentiation and have stopped expressing this pluripotency 
marker. Across the well highlands of PAX6 expressing cells, neuroprogenitors, were 
observed and anterior identity was verified using two distinct cell markers: OTX2 and 
FOXG1. In all cell lines, clusters of cells expressing PAX6 were highly abundant as well as 
OTX2 and FOXG1. No differences could be observed between the control and mutant cell 
lines demonstrating that induction of neuronal differentiation is not affected in MECP2-
mutant cells. On day 20, the presence of PAX6-expressing cells was much lower, since it is 
a primary progenitor cell marker while the expression of Nestin is already present and 
becomes even more abundant at day 30. The appearance of neuronal rosettes was 
identified by the combination of SOX2 and ZO1. The neuroepithelial cells (SOX2+) were 
radially arranged and showed signs of polarization with apical ZO1 expression. Although, 
we could observe similar proportions of rosette formation for all cell lines, their 
appearance was variable ranging from d12 to d17. At day 30, substantial maturation of 
neuronal progenitors was observed, as shown by the appearance of TUJ1-expressing cells 
Figure 4.10 - Stages of neuronal differentiation and cell type specific markers. Represented in the arrow are 
the 5 main differentiation stages: d0 – hIPSCs; d12 – Neuroepithelial monolayer; d20 – Radial glial cells; d30 
– Neuroepithelial cells and d120 – Neurons and astrocytes. Cell type specific markers are depicted by their 
expression (green boxes) or absence (orange box) at a given step of neuronal differentiation. Images 
representing each stage were published in (Shi et al., 2012).   
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already displaying an intricate network of axonal projections, and TBR2-expressing cells, 
revealing the presence of cortical neuronal progenitors (Figure 4.11). 
At the end of the differentiation process (Figure 4.12) neuronal maturation and glial 
differentiation were evaluated. A large number of GFAP-positive astrocytes could be seen 
interspersed with TUJ1-positive neurons and the same results were observed with MAP2. 
Layer-specific cortical markers, CTIP2, BRN2 and TBR1, were widely present in all cell lines 
further confirming the efficiency and specificity of the differentiation. Neuronal 
maturation was evaluated using antibodies against proteins involved in the transmission 
and regulations of the electrical impulse. The vast majority of neurons were SNAP25-
positive indicating the formation of pre-synaptic complexes. Although the dual SMAD 
inhibition protocol aims at the production of glutamatergic neurons, observed by VGLUT 
staining, the appearance of some GABAergic neurons is still a reality. Immunofluorescence 
using VGAT allowed the identification of very few cells positive for this marker. 
Immunofluorescence analysis of cell-type specific markers provides valuable 
information however, quantification is often difficult and cumbersome. In this regard 
mRNA quantification by real-time PCR (RT-PCR) using the same cell-type specific markers 
allowed a better characterization of the final cellular composition for each cell line. The 
differentiation process leads to the production of not only neurons but also glia, therefore 
we analysed the mRNA expression of GFAP and MAP2 to find the ratio between neuronal 
and glial production. If the ratio of two cell types is variable between the different cell lines 
this could mask potentially relevant results, especially those involving proteins expressed 
in just one of the cell populations. Therefore, this step is important not to compromise 
further analysis. However, once all proteins studied (except SNAP25) are expressed in both 
cell populations, normalization was performed to a ubiquitously expressed transcript 
GAPDH. High variability was observed in the expression of GFAP and MAP2 (Figure 4.13 
a)). We, also analysed mRNA expression of late markers such as VGAT and SNAP25 (Figure 
4.13 b)). VGAT expression is very low, in agreement with the results obtained with the low 
abundance of VGAT-positive cells by Immunofluorescence. SNAP25 has higher expression, 
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Figure 4.11 - Characterization of the first 3 stages of neuronal induction. In left column, representative images 
of day 12 (d12) staining are shown, positive for OTX2, SOX2 and FOXG1. In the middle column, representative 
images for d20 are shown, with positive signal to SOX2, PAX6, Nestin and ZO1. Finally, in the right column are 
represented the markers for day 30, with positive signal for PAX6, Nestin, TUJ1, ZO1, SOX2, TBR2. Images were 






Figure 4.12 - Characterization of final neuronal differentiation stage. Representative images of day 120 (d120) 
staining are shown with positive signal for TUJ1, CTIP2, GFAP, VGAT, VGLUT, SNAP25, MAP2, TBR1 and BRN2. 
Images were acquired by confocal microscopy, with 20x objective. Scale bars, 20/50 µm. 
 
a) b) 
Figure 4.13 Neuronal and glia-marker expression in cells derived from hIPSCs. a) Histogram shows relative 
expression obtained by qPCR showing mRNA levels of MAP2, a neuronal marker, and GFAP, a glial marker; b) for 
VGAT and SNAP25. GAPDH was used as internal loading control. 
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4.3.3 Adenosine receptors expression in hIPSCs and human brain sample 
After the appropriate hIPSCs characterization, mRNA of adenosine receptors was 
evaluated. In addition, we had the opportunity to perform the same analysis using human 
patient material. 
The results obtained from RTT female neurons show a tendency for an increase in A1R 
mRNA (0.005 ± 0.001, n=3), when compared to control lines (0.003 ± 0.001, n=2) (Figure 
4.14 a1,2)). However, given the striking degree of variability within each group and the 
reduced number of experiments (n), statistical analysis could not be performed. 
Surprisingly, even though the two control cell lines are of different gender, the variability 
between them is not high, suggesting that there are no gender specific differences. 
Interestingly, mRNA expression evaluated in a human temporal cortical sample obtained 
from a RTT patient showed higher A1R mRNA expression levels as compared to an 
equivalent cortical area from a healthy control (Figure 4.14 b)). This is in accordance with 
the results obtained in i) cortical samples from the RTT mice model, which revealed 
increased levels of A1R protein and in 2) neurons from RTT female-derived hIPSCs, which 
revealed a tendency for increased A1R mRNA expression. 
 
A2AR mRNA expression level in neurons-derived from hIPSCs revealed that lines RF1-1, 
RF2-1 and RM-2 (RTT lines) have a tendency for a higher expression levels than controls. 
However, these results present high variability depending on the differentiation round of 
the same cell line. In spite of that, there is a trend to have increased A2AR mRNA expression 
levels in RTT female lines (0.0003 ± 6.7e-005, n=3) when compared to the control group 
(0.0002 ± 1.1e-005, n=2) (Figure 4.15 a1,2)). 
The analysis of the human brain tissue revealed the opposite pattern in line with the 















Figure 4.14 - A1R mRNA relative expression in neurons-derived from hIPSCs and in RTT human brain. a1)  A1R 
mRNA relative expression for each cell line. GAPDH was used as internal loading control. a2) Grouped A1R mRNA 
expression: controls (Ct1, Ct2; black); RTT-Female (RF1-1, RF1-2, RF2; purple) and RTT-Male (RM-1, RM-2; blue). 
Values are presented in mean ± SEM. b) A1R relative expression in samples taken from healthy human temporal 









In parallel, ADK protein expression level was also evaluated in neurons-derived from 
hIPSCs to explore if molecular changes in this enzyme could be related with adenosinergic 
changes in RTT as detailed before. Western-Blot analysis showed high variability in ADK 
immunoreactivity and therefore no inference can be made (Figure 4.16 a1,2)). However, 
in Mecp2 KO mice, statistical analysis has already provided evidence for non-altered ADK 
levels in RTT model when compared to WT. 
 
 
Figure 4.15 - A2AR mRNA relative expression in neurons-derived from hIPSCs and in RTT human brain. a1)  
A2AR mRNA relative expression for each cell line. GAPDH was used as internal loading control. a2) Grouped 
A2AR mRNA expression: controls (Ct1, Ct2; black); RTT-Female (RF1-1, RF1-2, RF2; purple) and RTT-Male (RM-
1, RM-2; blue). Values are presented in mean ± SEM. b) A2AR relative expression in samples taken from 






4.3.4 BDNF signalling impairment 
Protein levels of BDNF, TrkB-FL and TrkB-Tc receptors were evaluated in neurons-
derived from IPSCs. 
BDNF mRNA expression was quantified by qPCR as described in methods.  Low BDNF 
mRNA expression level in both RTT-females (0.001 ± 0.001, n=3) and in the control group 
(0.003 ± 0.001, n=2) was detected. On the contrary, in the RTT-male lines there was higher 
expression of BDNF mRNA (0.102 ± 0.090, n=2) in both rounds of differentiation (Figure 
4.17 a1,2)). Contrary to what was observed for mRNA quantification of other target genes, 
the variability within each group is much lower. In the human cortical sample, the BDNF 
mRNA expression is similar in both the patient and the control (Figure 4.17 b)). In 
Figure 4.16 - ADK protein expression level in neurons-derived from hIPSCs. a1) Western-Blot analysis using 
primary antibodies recognizing ADK isoforms (~40 kDa) and β-actin (~42 kDa), used as loading control. a2) 
Immunoreactivity intensity of the ADK isoforms obtained in neuronal lines. Data were normalized to 










































conclusion, BDNF mRNA expression level might have a tendency to be increased in male 
RTT lines but not in female lines which show a small decrease.   
 
BDNF protein expression level was also quantified using the ELISA assay in 3 lines: Ct2, 
RM-2 and RF1-2. As seen in Figure 4.18, BDNF protein expression level are increased in 
both female and male mutant lines, contradictory to what has been previously described 
for female line. The BDNF transcript level in RTT female lines shows a clear tendency to be 
downregulated when compared to the control group and furthermore, in Mecp2 KO mice 
BDNF protein expression level seem to be also downregulated.    
a1) a2) 
b) 
Figure 4.17 – BDNF mRNA relative expression in neurons-derived from hIPSCs and in RTT human brain. 
a1)  BDNF mRNA relative expression for each cell line. GAPDH was used as internal loading control. a2) 
Grouped BDNF mRNA expression: controls (Ct1, Ct2; black); RTT-Female (RF1-1, RF1-2, RF2; purple) and 
RTT-Male (RM-1, RM-2; blue). Values are presented in mean ± SEM. b) BDNF relative expression in samples 





TrkB-FL mRNA expression analysis in neurons-derived from hIPSCs shows a tendency 
for lower expression in RTT lines with the exception of RF2-1 where a small increase is 
observed (Figure 4.19 a1)). Overall, there seems to be a slight tendency in RTT-females to 
have decreased expression of TrkB-FL (0.013 ± 0.003, n=3) when compared to the control 
samples (0.015 ± 0.001, n=2). No conclusion can be withdrawn from the RTT-male group 
since variability is too high (0.009 ± 0.005, n=3) (Figure 4.19 a2)). TrkB-FL mRNA expression 
in the temporal cortex of RTT patient shows a small increase when compared with the 
control (Figure 4.19 b)), in contradiction to what was observed in Mecp2 KO.  
 
Figure 4.18 - BDNF concentration in neurons-derived from hIPSCs. BDNF concentration (pg/mg), evaluated 





TrkB-FL protein expression level is consistently decreased in all RTT cell lines (Figure 





Figure 4.19 – TrkB-FL mRNA relative expression in neurons-derived from hIPSCs and in RTT human brain. 
a1)  TrkB-FL mRNA relative expression for each cell line. GAPDH was used as internal loading control. a2) 
Grouped TrkB-FL mRNA expression: controls (Ct1, Ct2; black); RTT-Female (RF1-1, RF1-2, RF2; purple) and 
RTT-Male (RM-1, RM-2; blue). Values are presented in mean ± SEM. b) TrkB-FL  relative expression in 




Finally, TrkB-T1 mRNA expression level is decreased in all lines, except in RF2-1 that 
shows similar transcript levels when compared to the controls (Figure 4.21 a1)). Strikingly, 
RTT-male (0.026 ± 0.002, n=2) TrkB-T1 mRNA expression is largely decreased when 
compared with control group (0.223 ± 0.030, n=2). The RTT-female group also shows lower 
TrkB-T1 receptor expression (0.137 ± 0.037, n=3) when compared with control, but with 
higher expression when compared with RTT-male group (Figure 4.21 a2)). No changes 
were observed when mRNA expression levels were assessed between the patient 
temporal cortex and the healthy control (Figure 4.21 b)). 
 
TrkB-Tc protein expression level is consistently decreased in all RTT cell lines with the 
exception of RF2-1 (Figure 4.22 a1,2)) contrasting with the data obtained in cortical 
samples from Mecp2 KO mice, where no differences were observed. 
 
Figure 4.20 – TrkB-FL protein expression level in neurons-derived from hIPSCs. a1) Western-Blot analysis 
using primary antibodies recognizing TrkB-FL (~140 kDa) and β-actin (~42 kDa), used as loading control. a2) 
Immunoreactivity intensity of the TrkB-FL obtained in neuronal lines. Data were normalized to respective 























































Figure 4.21 - TrkB-T1 mRNA relative expression in neurons-derived from hIPSCs and in RTT human brain. a1)  
TrkB-T1 mRNA relative expression for each cell line. GAPDH was used as internal loading control. a2) Grouped 
TrkB-T1 mRNA expression: controls (Ct1, Ct2; black); RTT-Female (RF1-1, RF1-2, RF2; purple) and RTT-Male (RM-1, 
RM-2; blue). Values are presented in mean ± SEM. b) TrkB-T1  relative expression in samples taken from healthy 








Figure 4.22 – TrkB-Tc protein expression level in neurons-derived from hIPSCs. a1) Western-Blot analysis 
using primary antibodies recognizing TrkB-Tc (~95 kDa) and β-actin (~42 kDa), used as loading control. a2) 
Immunoreactivity intensity of the TrkB-Tc obtained in neuronal lines. Data were normalized to respective 










































 In the present work, characterization of the adenosinergic system and BDNF signalling 
using different models, provided evidence that both are affected in RTT (see Table 5-1).  
However, given the high variability and low number of experiments using human material, 
and the discrepancy between the human and the mouse model, the conclusions are only 
speculative.   
 
Adenosinergic system 
 The involvement of the adenosinergic system in neurological disorders has been 
receiving increased attention since A1R and A2AR modulation have been shown to 
attenuate some symptoms of several disorders (see for review Gomes et al., 2011; Chen 
et al., 2007; Sebastião and Ribeiro, 2009). This suggests that the adenosinergic signalling 
is affected in these pathologies. Our lab was the pioneer exploring the involvement of 
Table 5-1 Summary of the obtained results. Full symbols represent results submitted to statistical analysis. 
Dashed symbols represent tendencies. ↓ decrease; ↑increase; = no statistical significant differences; ? -   
inconclusive; n.d. - not determined. 




the adenosinergic system in RTT.  
 The results presented in this thesis demonstrate that mRNA expression level for 
A1R is unaffected in the cortex of Mecp2 KO mice. However, previous data clearly 
demonstrated that A1R protein expression level was significantly increased in cortex of 
Mecp2 KO (Palminha, 2014). There is a clear discrepancy between A1R mRNA and protein 
expression levels. This could be explained by decreased degradation of A1R and/or 
increased translation by post-transcriptional modulation.  In fact, it is known that MeCP2 
modulates protein synthesis through the AKT/mTOR system, a pathway known to be 
impaired in RTT (Li et al., 2013).  
 Interestingly, in neurons produced from RTT-derived hIPSCs, the female lines show 
a tendency to exhibit increased level of A1R mRNA. In addition, in one cortical post-
mortem sample of a RTT patient, A1R mRNA expression level is also increased when 
compared to an age matched control. The mechanism underlying the overall increased 
levels of A1R remains undisclosed so far. However, we can speculate that this could be a 
compensatory mechanism in order to decrease the excitability associated to this 
pathology. Accordingly, in the brain of Mecp2 KO mice there is a tendency for 
hyperexcitability as changes in basal inhibitory rhythms have been observed (Calfa et al., 
2011a) as well as pre- and postsynaptic defects in GABAergic synapses (Medrihan et al., 
2008). Moreover, data from our lab, input output curves recorded from hippocampal 
slices of Mecp2 KO mice, show an increased basal synaptic transmission. In addition, 
hippocampal electrophysiological experiments performed using A1R agonist and 
antagonist strongly suggest decreased endogenous adenosine level resulting in failure 
to control excitation. As mentioned before, the increase in A1R protein could be a 
compensatory mechanism to fine tune inhibitory adenosine activity in spite of its low 
levels. Remarkably, this tendency was also seen in mRNA expression level on RTT-
derived neurons and in the human brain sample.  Quantification of protein expression 
level in human material will be important to validate these results.  
 To understand how and why adenosine levels are decreased in Mecp2 KO mice, 
among other possible scenarios, we looked at alterations in ADK expression levels and 
in its activity. This enzyme, together with ADA, is responsible for adenosine degradation, 
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and is found altered in some disorders associated with impaired inhibitory transmission, 
such as epilepsy (Aronica et al., 2011; Boison, 2013). Our results, however, do not show 
significant differences in ADK cortical levels in the RTT animal model and in neurons-
derived from RTT-hIPSCs. Functionally, it is not easy to evaluate whether ADK activity is 
altered, given other alterations in the adenosinergic signalling such as increased A1R 
protein expression, which can perturb result interpretation. Electrophysiological 
recordings performed in the presence of an inhibitor of ADK show a similar decrease in 
synaptic transmission in the hippocampal slices from Mecp2 KO and WT mice. This could 
mean that 1) the decreased level of endogenous adenosine is not due to an exacerbated 
ADK activity in RTT (otherwise ADK would have mediated an exacerbated depression of 
synaptic transmission in RTT model); and/or that 2) even with higher level of A1R, the 
increased adenosine level, resultant from inhibition of its degradation by ADK, is not 
sufficient to produce a similar decrease on synaptic transmission as seen in WT animals. 
Moreover, the increased desinhibition induced by DPCPX, a selective A1R antagonist, 
observed in the presence of ADK in WT animals reinforces the possibility of adenosine 
level being decreased in the RTT animal model.  
 Nevertheless, it will be interesting to explore the effect of other molecules 
involved in adenosine metabolism, such as ADA, and find the mechanism behind 
reduced adenosine levels. Some studies, describe the downregulation of mitochondrial 
gene expression, which results in reduced electron transport chain units and also 
reduced glucose metabolism. Lower levels of ATP, highly related with adenosine 
formation, could explain adenosine reduction (Li et al., 2013; Krishnan et al., 2015). 
Impaired adenosine levels could also be related with upstream steps in adenosine 
biosynthesis, like ATP endogenous levels. 
 The A2AR mRNA expression level, in Mecp2 KO mice, is not significantly affected 
however, protein expression level is severely decreased. In RTT human brain, mRNA 
expression is decreased, but in neurons-derived from female RTT-hIPSCs there is a 
tendency to have increased A2AR mRNA expression. These discrepancies could be 
related to the variability observed in the different cell lines. Alterations in A2AR in RTT 
need therefore further exploration. Interestingly, in spite of the possible reduction of 
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protein expression level of this adenosine receptor, its activation is still efficient in 
rescuing BDNF effects upon synaptic plasticity (Duarte, 2015 in preparation). 
 How adenosine alterations occur in RTT and how they underlie RTT’s pathology is 
a critical issue that must be explored since it could provide important clues on how RTT 




BDNF deregulation is a recurrent topic in RTT. The modulation of this neurotrophin 
expression is controlled by the MeCP2 protein, found to be mutated in RTT in more than 
90% of the cases. Several studies showed decreased Bdnf mRNA expression as well as 
decreased protein levels in MeCP2 KO mice (Chang et al., 2006; Abuhatzira et al., 2007; 
Wang et al., 2006; Li et al., 2013) but similar BDNF mRNA expression in human RTT brain 
samples (Deng et al., 2007). At the same time, the overexpression of this neurotrophin 
can improve some of RTT symptoms, demonstrating the high impact of BDNF in this 
pathology (Chang et al., 2006). Our results obtained from Mecp2 KO mice were 
concordant with the majority of literature where Mecp2 KO mice present lower 
expression levels of BDNF protein. Surprisingly, when we looked at BDNF expression 
levels, in RTT-derived neurons, there was a tendency to have increased BDNF expression 
protein level. If confirmed, these results could reveal different BDNF expression pattern 
in humans.  
Little was known about TrkB receptor expression in RTT. One study has shown 
increased TrkB-FL mRNA expression level in Mecp2 KO mice and in RTT human cortical 
brain samples, which could be a compensatory mechanism promoted by low BDNF 
protein levels (Abuhatzira et al., 2007) while the other described no differences in TrkB-
FL mRNA between mutant human neurons and control neurons (Li et al., 2013). In line 
with the last study, our data shows no significant differences in TrkB-FL mRNA level in 
Mecp2 KO mice. However, TrkB-FL protein expression level in Mecp2 KO mice 




No changes were observed in TrkB truncated receptors in Mecp2 KO both at the 
mRNA (truncated isoform T1) and the protein expression levels (TrkB-Tc) and the same 
was observed for the TrkB-T1 mRNA in the cortical human sample. However, in neurons- 
derived from RTT-hIPSCs, both TrkB-T1 receptor mRNA and protein expression levels 
(TrkB-Tc) show a tendency to be decreased, without the typical variability seen for the 
other observations increasing the validity of the results. An interesting hypothesis is that 
the increased levels of BDNF in RTT-derived neurons could be the result of a 
compensatory mechanism induced by the decreased level of TrkB.  
One interesting observation, that holds true both for the adenosinergic system and 
for the BDNF signalling is that, in Mecp2 KO mice, mRNA expression levels are not altered 
(A1R, A2AR and TrkB receptors) while quantification of the respective proteins are clearly 
changed. This observation might be related to post-translational and degradation 
mechanisms, as previously mentioned. However, another possible explanation is that 
the severity inherent to the Mecp2 KO model probably does not allow for compensatory 
mechanisms, acting at the transcriptional level that could restore normal protein 
expression.  
 
hIPSCs as RTT model 
The appearance of hIPSCs as a disease model is very recent, with no more than 6 
years of development.  In this work, the biggest issue was the variability found not only 
between gender-matched lines but also between independent rounds of differentiation 
from the same parental hIPSCs line. Part of this variability could be related to the 
multiple genetic and epigenetic alterations that occur during the reprogramming and 
differentiation procedures, such as the fixation of sporadic random mutations and the 
random X chromosome inactivation in female lines (Dajani et al., 2013). Another 
important source of variability is the efficiency of cortical neuron production that is 
prone to fluctuate and thus compromising the results. 
Even though we found some concordant tendencies between the human and the 
mouse models, we cannot truly understand what the real tendency in RTT-derived 
neurons is. This is further aggravated by the small sample size that, in the future, could 
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be solved by increasing not only the number of patient-derived hIPSCs lines but also by 
increasing the amount of independent rounds of differentiation.  
Cerebral cortex processes are not the result of the activity of one isolated type of 
neurons but of the interaction of both stimulatory and inhibitory neurons. One 
important pitfall of this approach is that the protocol used generates mainly cortical 
glutamatergic neurons failing to recapitulate the functional complexity of the brain 
(Buxbaum and Hof, 2013). This is likely to contribute to the differences found between 
the hIPSCs model, the human post-mortem sample and the Mecp2 KO mice.  
 
Overall, the results clearly point towards a dysfunction in BDNF and the 
adenosinergic system. Despite this, pharmacological activation of A2AR is able to rescue 
BDNF actions upon LTP in Mecp2 KO mice (Duarte, 2015 in preparation). Thus, adenosine 
receptor pharmacological manipulation is a promising therapeutic strategy to rescue 
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